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Abstract
Many drug overdoses in the United States are from prescription drugs, most of which are
classified as opioid pain relievers (OPRs) and commonly prescribed in emergency
departments (EDs) to treat pain. OPR abuse and addiction is a major public health issue.
Researchers have identified the role of various patient characteristics (race, gender,
demographics, etc.) in the variation in OPR prescription rates, but the contribution of
provider-type differences to that variation has not been exposed. The purpose of this
study was to evaluate the strength of the association between provider type and the
likelihood of an opioid prescription by ED providers using national-level population data.
Drawing from symbolic interaction theory, which served as the study’s theoretical
framework, it was postulated that the training and background of ED providers influence
their interaction and OPR prescription decisions. The National Hospital Ambulatory
Medical Care Survey 2015 data were used to evaluate the association between provider
type and the likelihood of an OPR prescription, and the possible confounding effect of
patients’ race and payment type. Logistic regression analysis showed that attending
physicians, consulting physicians, and physician assistants were more likely (OR = 1.491,
1.318, and 1.315, respectively) to prescribe an OPR in the ED, while controlling for age
and pain level. Both race and payment type had predictive relationships with the outcome
variable, but only payment type interacted significantly with provider type. These
findings can serve as the basis for evidence-based training, procedure guidelines, and
policy development, as well as inform patient-provider interactions, potentially leading to
safer, more effective pain management encounters in the ED.
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Chapter 1: Introduction to the Study
Introduction
Drug addiction is an epidemic that has gravely affected the United States health
care system over the last few decades. The number of drug-related mortalities has been
steadily increasing (see Figure 1), fueled, in part, by the rapid increase in deaths linked to
opioid abuse (National Academies of Sciences, Engineering, and Medicine, 2017).
According to Barnett, Olenski, and Jena (2017), there has been an increase in the
prevalence of opioid prescriptions, despite no significant changes in pain presentation
(see Figure 1). Today, opioid addiction is a problem for all regardless of social status as it
affects everyone including addicts, their immediate family, and their community at large
(National Academies of Sciences, Engineering, and Medicine, 2017).
As a public health problem, the opioid epidemic is uniquely tied to another major
health issue, that of pain management. There are millions of Americans who are caught
between the dilemma of needing to reduce their chronic pain and their use of powerfully
effective but potentially addicting analgesics (Committee on Advancing Pain Research,
Care, and Education, 2011). Responding to the opioid epidemic has been challenged by
the fact that opioid abuse sometimes originates with an authorized prescription for the
drug (Lembke, 2016; Sinnenberg et al., 2017).
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Figure 1. Death from opioid overdoses. Reprinted from “Overdose Deaths Involving
Opioids, Cocaine, and Psychostimulants — United States, 2015–2016,” by P. Seth, L.
Scholl, R. A. Rudd, and S. Bacon, 2018, MMWR. Morbidity and Mortality Weekly
Report, 67(12), p.349-358. Copyright 2018 by Centers for Disease Control and
Prevention.
Background
Pain is the most common complaint with which adult patients in the United States
present to the emergency room. Out of the 131 million emergency department (ED)
encounters across the United States in 2011, pain-related ailments were the most frequent
reason for ED visits (Weiss, Wier, Stocks, & Blanchard, 2014). And in 2015, among
those aged 18-64, approximately 34% of all ED visitors had an opioid ordered or
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prescribed to them (Yacisin, O’Connor, & Akinseye, 2018). Moreover, there has been a
significant increase in the rate of opioid prescription in EDs over a decade now, an
increase not accounted for by any increase in the presentation of pain-related complaints
(Mazer-Amirshahi, Mullins, Rasooly, Van Den Anker, & Pines, 2014; Murthy, 2016;
Patel & Afshar, 2017). The cause and the effects of this increase in opioid prescription
and its possible connection to the present-day opioid epidemic has garnered the attention
of researchers.
There are several options for treating patients who present with pain, the most
common of which is to prescribe an analgesic. Opioids, though very effective as a pain
reliever, are also highly addictive, and many people who are initially prescribed these
medications for medical purposes end up misusing them (Broida, Gronowski, Kalnow,
Little, & Lloyd, 2017; Jeffery et al., 2018; Substance Abuse and Mental Health Services
Administration, 2016). Unfortunately, there are opioid-naive (never used opioids before)
patients who become addicted after having been introduced to opioid drugs at the ED
(Hoppe, Kim, & Heard, 2014). Additionally, patients dealing with health issues and who
more frequently visit the ED tend to have a higher prevalence of opioid abuse (Han et al.,
2017). This finding implicates ED opioid prescription in the opioid epidemic dilemma.
Pain management, the practice of treating patients presenting with all types of
pain, is essential to quality health care, but it may be hindered by implicit biases and
disparities in analgesic therapy. Studies focused on opioid prescription rates in
emergency settings have shown some of the many factors related to the biases between
the patient and their prescriber (Barnett et al., 2017; Knopf, 2017). Some of the factors
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that account for the variation in prescription rate include patient characteristics such as
age, gender, race/ethnicity, and source of payment (Hollingshead, 2016; Knopf, 2017).
Other researchers have uncovered that patients’ race and socioeconomic status are the
major contributors to opioid prescription rate variation (Singhal, Tien, & Hsia, 2016;
Sinnenberg et al., 2017). These prescription rate variations have had serious implications
for the disparity in pain management among minority population groups in the United
States (Singhal et al., 2016).
Yet, other studies on the role of the ED in the rampant abuse of opioid drugs in
the United States have implicated not only the characteristics of ED patients, but those of
ED health care professionals who do the prescribing (Bartley et al., 2015; Pomerleau,
Schrager, & Morgan, 2016). Researchers have found that prescriber- or provider-type
qualities including age, gender, race, level of experience, and specialty influence the rate
at which opioids are prescribed (Porucznik, Johnson, Rolfs, Sauer, & Porucznik, 2014;
Sinnenberg et al., 2017). In a study of Medicare recipients, Barnett et al. (2017) found
that the rate of opioid prescription in the ED varied significantly, from 7.3% to 24.1%,
among different hospitals. Another study demonstrated the significant amount of
variation that can exist among providers at the same institution, for patients who present
with the same condition (see Figure 2; Hoppe, Mcstay, Sun, Capp, & Hess, 2017).
Studies like these point to the complicated nature of opioid prescribing and the complex
involvement of prescriber bias. Understanding the prescriber to patient interaction and the
factors involved in prescriber decision-making is important to the development of
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policies and procedures that are aimed at curbing the opioid pain reliever (OPR) abuse
epidemic.
The burgeoning opioid crisis made evident the need for policy re-evaluation, and
consequently in 2013 many different States implemented new procedures (Beaudoin,
Janicki, Zhai, & Choo, 2018). These new value-based practice guidelines for physicians
were intended to influence the way they practice medicine and streamline their
prescription decisions and behavior. However, recent research revealed that these policy
changes were ineffective and 4 years later the expected savings were unrealized (Bonfrer,
Figueroa, Zheng, Orav, & Jha, 2018). Regarding opioid prescription in the ED, although
the overall rate decreased slightly, the variation in frequency of opioid ED prescription
among provider type persisted (Beaudoin et al., 2018). According to Vivolo-Kantor et al.
(2018), despite data implying a stabilizing of prescription rates, the opioid overdose
problem is worsening, with rates continuing to rise from 2016 into 2018. The exact
reasons for and the underlying drivers for the differences in OPR prescription rates
among the various provider types remain unclear.
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Figure 2. Variation in opioid prescription rate in an urban academic hospital ED. (Hoppe
et al., 2017).
Understanding the role of the provider in the ED is an important component of
opioid prescription variation. As Michael et al. (2018) concluded, more research is
needed to counter cognitive dissonance and the absence of self-awareness among
providers and to foster greater ED prescribing policy compliance. Understanding the
vulnerabilities and unconscious biases involved in ED OPR prescription variation can
help medical groups design improved prescription guidelines and standardize emergency
responses to pain (Lembke, 2016). Hopefully, the findings from this research will inform
providers, policy makers, and the stakeholders involved in reducing the risk of OPR
addiction and help promote more effective solutions to the opioid epidemic.
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Problem Statement
There are many factors, mostly related to the nature of the interaction between the
patient and the prescriber, involved in the prescription of opioids. Unraveling the
variables associated with an initial opioid prescription, recurrent use, and eventual abuse
is critical to a sustainable solution to the OPR epidemic (Beaudoin et al., 2018; Csiernik,
2016). Many studies underscore the role of patients’ characteristics, namely their race,
ethnicity, age, gender and demographics, on the rate of ED opioid prescription (see
Barnett et al., 2017; Han et al., 20147; Knopf, 2017; Manchikanti et al., 2012; Pletcher,
Kertesz, Kohn, & Gonzales, 2008; Tamayo-Sarver et al., 2003). Fewer researchers have
examined the role of the provider on the rate of ED opioid prescription, however; these
studies have yielded evidence of significant variation but have been limited by size and
scope (see Hoppe et al., 2014; Pomerleau et al., 2016; Smulowitz, Cary, Boyle, &
Jagminas, 2016). It is now believed that understanding the nature and the impact of
provider type on the rate of ED opioid prescription is essential to the development of
provider-specific prescription guidelines that improve ED pain management strategies
and minimize the contribution to the opioid crisis (Ganem, Mora, Varney, & Bebarta,
2014; Michael et al., 2018).
Purpose of the Study
There are several studies concerning the issue of ED opioid prescription but few
have included an examination of the relationship between provider type and the rate of
opioid prescription, and those that have were either pilot studies or limited to a specific
hospital or patient group. This quantitative analysis was the first, according to my review
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of the literature, to evaluate the strength of the association between provider type and the
likelihood of an opioid prescription by ED providers using population data collected on
the national level. I sought to explore the complicated dynamics between opioid
prescription and potential opioid abuse by highlighting the impact, if any, that different
types of health care professionals have on the opioid prescribing rate and rate variability
in EDs across the United States.
Research Questions and Hypotheses
The focus of the study’s three research questions (RQs) was on providing insight
into the proposed association between the provider type and the probability of emergency
department opioid prescription. The RQs and corresponding hypotheses were, as follows:
RQ 1: Is there a statistical significant association between provider type and
probability of opioid prescription in the ED?
H01: There is no significant association between provider type and probability of
opioid prescription in the ED?
Ha1: There is a significant association between provider type and probability of
opioid prescription in the ED?
RQ 2: Is the association between provider type and the probability of opioid
prescription influenced by the race/ethnicity of the patient?
H02: The association between provider type and the probability of opioid
prescription is not influenced by the race/ethnicity of the patient.
Ha2: The association between provider type and the probability of opioid
prescription is influenced by the race/ethnicity of the patient.
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RQ 3: Is the association between prescriber type and the probability of opioid
prescription is influenced by the patient’s “expected source of payment” variable?
H03: The association between prescriber type and the probability of opioid
prescription is not influenced by the patient’s “expected source of payment” variable.
Ha3: The association between prescriber type and the probability of opioid
prescription is influenced by the patient’s “expected source of payment” variable.
Theoretical Framework
Researchers commonly use symbolic interaction theory (SIT), also referred to as
the symbolic interactionism, to study how individuals behave in different settings. SIT is
a social science theory and provides an explanation of the nature of the different types of
relationships that exist within a society (Hari, Henriksson, Malinen, & Parkkonen, 2015).
The theory is premised on the idea that a society is the result of everyday interaction
among people and that, as a result of these social exchanges, individuals develop
unconscious patterns of behavior (Aksan, Kısac, Aydın, & Demirbuken, 2009). Several
decades ago, health care researchers, specifically nursing researchers, applied SIT to
explain how patterns of hierarchy influenced the nurse-patient relationship and the
outcome of nursing care (Chapman, 1976). More recent researchers have used SIT to
develop models or causal pathways for certain health problems to guide the development
of health intervention strategies (Noyes, 2017).
According to SIT, individuals live in a symbolic world, and the nature of any
social interaction is subconsciously influenced by the particular interpretations of the
symbols encountered as individuals interact with others (Aksan et al., 2009). This theory
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is premised on three main assumptions that provide a basis for analyzing interactions to
find solutions to problems of a social nature. These assumptions include the following:
(a) an individual’s behavior is based on the meaning he or she has constructed about his
or her world, (b) an individual’s action is in response to the meaning he or she has
assigned to the actions of others, and (c) the meaning that an individual assigns to the
behavior of others is based on his or her own personal experience (West & Turner, 2018).
According to Redmond (2015), humans are social beings and they create their world
based on social interaction, but they are also actively thinking (as opposed to passive
conditioning) beings that are constantly defining and redefining their world based on their
interactions with others.
Social science frameworks may be beneficial to health care research design and
improve the understanding and interpretation of the findings. The positivistic approach,
with its propensity for quantification analysis, is more common in public health and
epidemiology research. However, social science frameworks are better suited to
understanding issues of drug addiction and the social nature of its impact and to
developing suitable intervention strategies (Maycock, 2015; Patulny, Siminski, &
Mendolia, 2015). In this study, I assumed that the patterns of behavior of health care
practitioners working in the ED are influenced by their training and background and that
these factors affect their interactions with patients. I also assumed that practitioners’
prescribing decisions are also affected by their perceptions of their patients based on their
physical qualities (as reflected by their race or age) and their socioeconomic status (as
reflected by the source of payment). It is these assumptions that I attempted to provide
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insight on in conducting this investigation. The findings should elucidate the nature of the
relationship between the ED provider type and patients and its effect on opioid
prescription dynamics.
Nature of the Study
This study involved a quantitative statistical analysis of retrospective crosssectional data. I used data from the ED section of the National Hospital Ambulatory
Medical Care Survey (NHAMCS); the relevant variables were from those who visited the
ED and were not admitted (CDC/National Center for Health Statistics [NCHS], 2017).
The outcome or dependent variable (DV) was categorical and was the Yes/No
(dichotomous) response to whether an opioid was prescribed during the visit. The
independent variable (IV), provider type, was also categorical (attending physician,
resident physician, physician assistant, nurse practitioner, and physician consultant). To
answer the first research question, I used a univariate logistic analysis to evaluate the
association between the IV and DV, while controlling for age and painscale measure. For
the second and third research questions, multivariate logistic analyses were used to assess
the effect of potential covariates (race/ethnicity of patient or the expected payment plan
of the patient) on the main (provider type/prescription rate) regression formula.
Assumptions
I analyzed secondary data from the 2015 NHAMCS. The makers of the survey
collected cross-sectional data on patient visits to the EDs from all 50 states in the United
States, excluding those from federal, military, and Veterans Administration hospitals for
the year 2015 (NCHS, 2015a). The data they collected were generated from the electronic
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records associated with patient record forms or PRFs and were based on patient visit
weight estimates, for which the relative standard error was less than or equal to 30%
(NCHS, 2015a). The NHAMCS survey is one of many surveys administered by National
Health Care Surveys to record health care utilization activity among the different types of
health care providers across the United States.
The NHAMCS data is shared publicly for analysis and the assumptions is that the
data were accurately collected and recorded and is representative of the entire population.
The sampling was conducted with a four-stage sampling design: (a) primary sampling
unit (counties), (b) hospitals within those primary sampling units, (c) clinics within the
outpatient departments, and (d) patients visits within emergency service areas (NCHS,
2015a). Of the 457 EDs selected, 377 were eligible, resulting in a 70.8% (68.7 weighted)
response rate (NCHS, 2015a). The electronic PRF data from 100 randomly selected
patients from each of the participating institutions were collected over the systematically
assigned 4-week reporting period (NCHS, 2015a). The data was then cleaned, compiled,
and published on the CDC/NCHS website.
The NHAMCS incorporates various measures of quality control to ensure the
accuracy of the data collected. Attempts were made to minimize bias by using a
multistage estimation technique that included: 1) trimming the overall probabilities for
institutions that may be overrepresented; 2) weighting the responses from similarly sized
institutions to account for non-responses; and 3) accounting for the seasonal reporting by
shifting the extra weights among EDs in same quarter of the year (National Center for
Health Statistics, 2015a). Internal validity testing revealed that the missing data may lead
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to added variances, but the possibility of a Type I error could be minimized by choosing
an alpha of 0.01 instead of 0.05 for the test of significant differences (National Center for
Health Statistics, 2015a). Unlike in previous years, for 2015, all data were collected by
assigned ‘Census Abstractors’ specially selected and trained by the U.S. Census Bureau
(National Center for Health Statistics, 2015a).
Limitations
The limitations of this study are few and are based on the objective of the research
questions. Even though the NHAMCS collects data from EDs as well as outpatient
departments, only the ED data have been made public. Since the analysis uses crosssectional survey data, no causal inferences (only correlational) can be made from the
results. Also, the approximately 70% response rate, based on eligibility, could introduce
some response bias (National Center for Health Statistics, 2015a). Finally, this study is
limited to a specific time period, the year 2015 and to very specific independent
(provider-type, race, payment source) and outcome (rate of opioid prescription) variables.
Given that the study is limited to U. S. hospitals, the findings are valid and generalizable
to ED settings in the U. S. alone.
Significance
The problem of opioid epidemic is getting progressively worse and has,
deservedly so, become a most pressing public health concern. In 2010, of the 33,329
deaths from overdose of prescription drugs, 16,600 were the opioid analgesics medication
(Poon & Greenwood-Ericksen, 2014). Over the next decade and a half, an increase in
prescription drugs use paralleled an increase in heroin use and consequently an increase
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in related deaths. Among those who try heroin for the first time, four out of every five
had already been abusing prescription pain relievers (Poon & Greenwood-Ericksen,
2014). OPR abuse usually begins with a prescription and end with addiction.
There has been a reported 568,699 drug overdoses between 1999 to 2015 in the
US, and in 2015 alone, 63% of the drug overdose deaths were caused by opioids (Puja
Seth, Scholl, Rudd, & Bacon, 2018). According a report based on data from the Center
for Disease Control and Prevention, “deaths from synthetic opioids are up 72%” (Rudd,
Seth, David, & Scholl, 2016). Similarly, the age-adjusted rates for overdose of OPR has
doubled from 2015 to 2016, with the rate an increase of almost 300% among Hispanics
and an increase of approximately 400% in the Washington, DC area (Puja Seth, Scholl, et
al., 2018). There is no doubt that the abuse of OPR is at epidemic proportion in this
country and if not addressed will get progressively worse.
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Figure 3. Death from Prescription Opioid Overdose. (Puja Seth, Rudd, et al., 2018).
The role of ED prescription in the opioid crisis is worth researching for a number
of reasons. In the US, over two million individuals are dealing with an addiction to
prescription opioids, and another 12 million are currently abusing opioid drugs in some
form or another (Hughes et al., 2016). A study by Hoppe, et al. (2015) found that one in
every six patient discharged from the ED was prescribed an opioid and that ratio was
almost doubled when those admitted to the hospital were included. Research has
indicated that abuse and addiction can be initiated from a legitimate opioid prescription
(Butler et al., 2016; Lembke, 2016). Understanding the connection between ED
prescription and opioid abuse and addiction may help create more effective policy.
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The aforementioned numbers indicate the severity of the opioid epidemic and the
possible role that ED prescribing may play. Therefore, tailoring solutions and strategies
that effectively address the underlying drivers of this issue is critical to the success of any
intervention program. It is the objective of this research to contribute information related
to the opioid epidemic and opioid pain reliever prescription, specifically how the ED
prescriptions rate varies and is influenced by the various ED provider-types. Educating
the stake-holders and policy writers about this subject of prescription rate variation could
be important to responding to and minimizing the negative impact of the opioid epidemic.
Positive Social Impact
The results of the opioid epidemic are widespread and far-reaching, and even
today the rate of opioid abuse continues to rise (Vivolo-Kantor et al., 2018). It has now
gotten much media attention, with the President Donald Trump and First Lady, Melania
Trump getting involved to find a solution to this national crisis. The apparent solution is
demanding of a multifaceted approach that combines the resources and expertise of all
the stake-holders, of which the ED prescribers play an important role (Mazer-Amirshahi
et al., 2014). The first step in reducing the impact of this dilemma is knowledge of the
contributing factors and awareness of the nature of the role of each factor. The current
need is for timely, insightful information gathered from the field, on which evidencebased intervention programs can be developed and implemented.
The positive social change implication of this study is two-fold. First, the
information generated will add to the awareness of the providers about their biases and
their partialities, both conscious and unconscious, and how those biases influence their
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decision-making process and their prescribing behavior. Second, the information from the
findings combined with other resources used to improve upon the existing policies and
guidelines, fostering safer prescribing practices and better pain management services in
the ED. This type of impact of beneficial to the patients, the providers, the institutions,
and the policy makers as well as the society at large.
Summary
The problem of prescription drug abuse in the US is a major healthcare issue, and
the increasing opioid addiction is partly responsible. Responding to the opioid crisis has
been complicated by the fact that it is so closely linked to another healthcare dilemmapain management. Pain is the most common reason for visiting the ED and every year
several million patients leave with a prescription for an opioid pain reliever.
Unfortunately, many of these patients end up abusing these drugs, others become
addicted, and some may even die as a result of the abuse. Several studies have found that
the rate of opioid prescription in the ED is influenced by the patient’s characteristics,
including race, gender, age, and SES. Other small-scale studies have implicated certain
qualities of the providers as well. The objective of this study is to investigate the role that
provider-type differences has on the opioid prescription rate variation. This research was
a large-scale study, utilizing data from the National Hospital Ambulatory Medical Care
Survey (NHAMCS). The objective is that the findings will bring awareness to the issue
and provide important insight guiding policy and procedure development related to the
opioid epidemic.
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Chapter 2: Literature Review
Introduction
The objective of this literature review is to illustrate the challenges related to pain
management in the U.S. health care system and to detail the role of various risk factors
driving the opioid epidemic. Much of the focus and research has been placed on patientrelated factors and their role in the worsening opioid epidemic. But despite the recent
implementation of prescription guidelines and other patient-related strategies for opioids,
variation in prescription rates, especially among the various ED providers, continues. A
few pilot studies have revealed that there are physician-related biases that affect their
prescribing decisions and that these differences contribute to the variation but, without
extensive, large-scale investigation, it is difficult to use the information. An increased
understanding of the factors, some of which are unconscious, that influence the
prescribing decisions of ED providers may help hospitals develop meaningful
interventions that help to curb the rise in the rate of prescription opioid and positively
impact the opioid abuse epidemic in the United States.
Chapter 2 begins with an overview of my literature search strategy, which is
followed by a description of the theoretical foundation for my research. The literature
review begins with a discussion of the history of pain through the ages and the various
approaches used to deal with this longstanding health condition. The section that follows
includes details on the history of pain management and the development of the field as it
is known today. It also includes information about analgesics and how opium-derived
drugs became some of the most common pain relievers. The next section includes a
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description of the rapid rise in prescription opioid and opioid abuse, concurrent with the
rise in opioid-related injuries. In addition, in this section, I discuss the conditions that
facilitated addiction to opioids and the resulting epidemic, as well as the factors that
predispose individuals to addiction. The final section of the literature review includes
relevant research on the issue of opioid prescription and the variation in prescription rate
and their role in the epidemic. The section closes with the particulars of the studies on ED
prescription variation, with emphasis on the reasons why this is an important area that
should be the subject of future research. The chapter ends with a summary of key points
and a transition to Chapter 3.
Literature Search Strategy
For this literature research I used several online databases focusing on health and
epidemiology. Most of the journal articles were found in the PubMed database, but
several came from Google Scholar, Elsevier, Wiley, ProQuest, Medline, Ebscohost,
Tandfonline, and CINAHL. I accessed these databases from Walden University Library.
The search terms used included opioid, opioids, opioid epidemic, pain, pain management,
opioid prescription, opioid addiction, ED provider, opioid mortality, opioid abuse, and
opioid prescription variation. These were used either individually or in various
combinations with the Boolean operators AND, OR, or NOT to restrict the results to
those that were relevant and useful. I obtained some of the statistical information from
websites belonging to the U.S. Department of Health and Human Services and
institutions under it such as the Food and Drug Institution (FDA), National Institutes of
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Health, and the CDC, especially its measles, mumps, and rubella section. I also utilized
the journal sharing website ResearchGate to obtain articles not available in the databases.
There were many research articles to choose from, as the opioid epidemic has
become a very popular topic of study. I narrowed my search to articles relevant to the
topic of the role of opioid prescription rates in the opioid epidemic. Finding research
articles that specifically addressed ED provider prescription variation was a bit more
challenging. Reviewing the objective and the abstracts of each article provided valuable
insight into the usefulness of the article to the study. Prioritizing the original research
articles that reported important findings required a more extensive review of search
results. Once I deemed articles relevant, I added them to an online Mendeley account and
later to the offline version once it had been updated. In the offline account the articles
were tagged and filed in various folders to facilitate easy retrieval of reference
information for the reference list.
Theoretical Framework
Theoretical Concept of Symbolic Interaction Theory
I used the theory of symbolic interaction as the theoretical foundation for this
research. The idea of SIT comes from social science and is credited to George Herbert
Mead. Mead was a psychologist who laid the foundation for a unique approach into
human social behavior by expanding on the concepts of mind and me (Benzies & Allen,
2001). It would only be labelled symbolic interaction theory by subsequent researchers
who adopted his approach and included concepts of I and me. In essence, SIT states that
individuals’ concept of their world is based solely on their interpretations of what they
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perceive in their world and it is this interpretation that governs their behavior (Benzies &
Allen, 2001). SIT helps researchers to explain human behavior from a different
perspective than simply what can be observed--from underlying thoughts and
subconscious motivations.
Those who subscribe to SIT contend that the world individuals live in is made up
of symbols and that all social interactions are based on individuals’ interpretations of
those symbols (Aksan et al., 2009). According to symbolic interactionists, there are three
main assumptions that underly the theory and its use. They include the following: (a) that
all human behavior is influenced by the individuals’ perception of their world; (b)
individuals’ perception of their world is based on their interpretation of the symbols, both
material and immaterial symbols; and (c) the interpretation that individuals assign to each
symbol they encounter is based on their historical experience with that symbol (West &
Turner, 2018). The SIT concepts define human interaction as dynamic in nature, one that
is constantly being created and recreated by individuals’ many social encounters and the
actions they take in response to their interpretations of these encounters (Redmond,
2015).
Symbolic Interaction Theory in Nursing
Symbolic interaction theory (SIT) has been used for decades in the fields of
psychology and social science as it useful for understanding and interpreting the different
social dynamics that make up the society (Hari et al., 2015). According to Aksan et al.
(2009), SIT not only explains the nature of the interactions and why they happen, it also
provides insight into the unconscious patterns of behavior that exists in many social
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settings. But SIT has been found to a flexible theory and has moved beyond the sciences
to other fields including medicine and healthcare. It was first used several decades ago in
nursing research to understand the dynamics involved in the nurse-patient relationship
and how that relationship affects patient’s health outcome (Chapman, 1976)) The
researchers believed that combing sociology and nursing could provide insight into the
behavior of both groups (nurse and patient) and how the patterns of power and
compliance overlap to meet the respective objectives of each and how that insight could
benefit both (Chapman, 1976). The research was a success and it provided the impetus
for more research in the health field with SIT as the framework for analysis.
The social dynamics between the patient and the healthcare provider turns out to
be quite suitable for the SIT based study. Another study ten years later, used SIT to study
the nurse-patient interaction, but specifically in the emergency department setting. This
study collected data from the in-depth interviews to understand the social symbols that
influenced the nature interactions between and the behavior of the nurses towards their
patients (Byrne & Heyman, 1997). The symbolic interaction theory was used to interpret
the attitudes of their role and purpose as well as their discernment of their patient’s
behavior and to direct the analysis of the data. The definitions of their role were
prioritized by a few factors and this governed their care approach. These factors included:
treating the patients’ injury; providing urgent care; the smooth running of the department;
and fulfilling the role according department rules (Byrne & Heyman, 1997). The results
indicated that the nurses were under pressure to ensure that the ED was running smoothly
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during their shift, and this pressure resulted in them spending less time and poor
communication with their patient (Byrne & Heyman, 1997).
Researchers used the theories like SIT to dig deeper into the meaning of the
results, as was necessary if they were going to use the results to develop an intervention
strategy. This led them to note that the nurses training and years of experience, in the ED
and as a nurse in general, influenced how much pressure they felt and how much time
they felt necessary to understand the concerns and anxieties of their patient (Byrne &
Heyman, 1997). Some nurses needed less interview time and even used the ‘popping in’
technique as a means of calm their patient’s anxieties (Byrne & Heyman, 1997). Overall,
the research was groundbreaking as it had led the way to what would become quite
common- the use of social science theory in healthcare research.
Symbolic Interaction Theory in Mental Illness
SIT has also been used to provide the theoretical framework needed to interpret
research findings as it relates to the problem of mental illness and the associated social
stigma. A comprehensive literature review research on mental illness used SIT to identify
the behavioral factors that may be hindering patient recovery or the administration of
proper care (Roe, Joseph, & Middleton, 2010). The new policies that shifted focus on
providing support by promoting improved sense of well-being as opposed to only curing,
treating, or alleviating patient’s dysfunction. The proper implementation of these
intervention would be largely dependent on the interaction between the patient and their
healthcare professional, which is in turn influenced by the providers’ attitude towards
their patient and their condition. The stigma of being a psychiatric patient, their
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perception of the service they are provided could either enhance or exacerbate the mental
and emotional issues. SIT was used to identify the context, the discourse and the
expectations and interpretations of the variables in the cultural and social and critical
examination that includes the exposures of hidden motives and unconscious biases (Roe
et al., 2010). The findings, as interpreted by the SIT, revealed the importance of policies
that address the social issues that contribute to the mental illness (Roe et al., 2010). The
support provided by a positive social interaction, the most important of which is with
their healthcare providers, can enhance the recovery process. SIT was also used to design
intervention strategies that would foster a more constructive social interaction between
the mental health patient and their caregiver.
Symbolic Theory in Current Research
SIT provides the framework for the research process that involves a social setting
and fosters an understanding of the worldview possessed by each of the parties involved,
their definition of the relevant symbols and the interpretation of these symbols that
motivate the actions and behavior (Hari et al., 2015). Interpretations of the social symbols
are governed by external as well as internal ideas, derived from past social experiences,
with a presumption of a predefined ‘me’ and then what does this action mean to the ‘me’
I believe myself to be, are at the foundation of social interaction rituals (Patulny et al.,
2015). The dynamic relationship between the self and the society is created by and then
altered by further interactions based on the premises of the behavior of others, their
interpretation of symbols their behavior conveys, and the reaction and dynamics
generated from their response (Roe et al., 2010). The best method for interpreting human
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behavior is through an internal and an external frame of reference, helps individuals make
sense of both.
The use of SIT and other social science theories in quantitative healthcare
research is having a positive impact. Like with the nursing research, SIT revealed that a
definition of one’s work priorities and perceptions of their patients both had a major
influence on the nature and quality of the communication, and it affected the care that the
patient received. Positivism and other theories of descriptive, correlational, causalQuasi-Experimental, and Experimental were more common, but the social sciences are
proving appropriate for select issues of healthcare that have a distinct social aspect
(Maycock, 2015; Patulny et al., 2015). Theories like SIT can not only be used to design
the research, it can elucidate the findings and then guide the development of an effective
intervention strategy. Researchers are finding that defining nature of the interactions and
subsequently creating programs for healthcare intervention is easier if theories like SIT
are used to model the problem (Noyes, 2017).
For this current research program, SIT was chosen because of its propensity to
enlighten social interactions, the symbols involved, and the patterns of behavior created.
Here the ED providers as healthcare practitioners are interaction with their patients in the
ED setting and this interaction is influencing the rate of opioid prescription and
eventually having an impact on potential opioid abuse and misuse. Since most of the
prescribing decisions are made subconsciously, a theory like SIT helps to uncover some
of these biases that are below the surface and make them more aware of their behavior.
Understanding the nature of the social interaction and the factors that are involved could
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provide valuable information for crafting new policies governing prescription drugs or
improving current ones.
This current study proposes that there some very salient factors that influence
prescribing decisions and these create prescribing patterns among the different type of
providers. Characteristics such as a patient’s race/ethnicity and their SES as perceived by
the provider create stereotypes that then influence who get prescribed an opioid
analgesic. These providers, based on their level of training, their area of specialty, their
respective roles in the ED, can factor subconsciously and create these persistent patterns
of variation in prescription rates. Using theories like SIT to guide research can bring
these subconscious factors to the awareness of the ED providers as well as the policy
creators.
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Literature Review Related to Key Variables and/or Concepts
The History of Pain
Pain in ancient times. Pain is a universal human experience and the oldest
medical problem, it is also the most common reason for seeking medical care (Tompkins,
Hobelmann, & Compton, 2017). Pain is an inevitable part of being alive, as all living
creatures who poses a central nervous system share in the experience of pain. But pain is
more than a biological reaction to a painful stimulus, it is also a complex mix of cultural,
social, and psychological factors that play a role in its manifestation (Germossa, 2018).
Pain has come to serve as an important signal of disease or injury in the body and its
presence has a major impact on the quality of life (Colliers, 2018). But pain and the
treatment of pain has had a long and fascinating history that is worth exploring.
The history of pain and pain treatment is filled with many colorful tales and in the
earliest records. Those involved in treating the sick and practicing the art of healing have
always been challenged with balancing the patients need for pain relief with that of any
unwanted side effects of the administered pain therapy. In ancient times pain was
regarded as the work of demons or evil spirits inhabiting the body of the sufferer. In those
days, pain management was relegated to the work of the shamans and the priests who
were also the medicine men and women. Unfortunately, during those ‘dark ages’ attempts
at pain relief focused more on the exorcising of the evil spirits from the body and not so
much relieving the discomfort (Olson, 2013). The ceremonies involved a combination of
magical and religious rituals that included incantations, scarifications, and the application
of various pumice, bloodletting, vomiting (Colliers, 2018). Regrettably some of these
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rituals are still practiced in remotes parts of the world, with the same of the same results,
namely continued agony for the sufferer.
Across the globe, history of pain has been marked with very little understanding
of the cause of pain but with prodigious attempts to alleviate it. As time progressed,
beliefs about ideas of pain evolved slightly from demon possession to that of the evitable
suffering of the soul, brought on by the sinful nature of all ‘fallen beings’ (Sabatowski,
Schafer, Kasper, Brunsch, & Radbruch, 2004). Pain was regarded as Divine justice and
any effort made to alleviate it was considered interfering with the will of God. But this
view of the inevitably of suffering was not held by everyone and there was ongoing
exploration into the various methods of relieving pain. These early research into pain
relief coincided with the birth of the first modern-day medical schools in Europe
organized for training physicians and standardizing the practice of medicine.
Interestingly, more than half of the formulations documented at these then new
medical schools were for the treatment of pain (Sabatowski et al., 2004). These potions
were mostly anesthetic in their effect and were used for surgical procedures such as
amputations and trepanning (drilling into the skull). The most effective of these potions
were the Laudanum- a solution of opium mixed with alcohol that allowed for controlled
and standardized administration of the drug for various ailments. The invention of this
tincture proved to be one of the most monumental invention in the practice of medicine
up to that time (Sabatowski et al., 2004). But even then, its use was not without the
warning of potential of addiction, and the religious community was still opposed the
administration of any unholy drug with a conscious altering effect.
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Pain during the Renaissance. The renaissance marked the rebirth of science and
inquiry in the practice of medicine. Humorism, though an ancient ideology created by the
Ancient Egyptians and promoted by Hippocrates, was popular once again. Humorists
believed in the holistic working of the body and that one’s health and temperament
controlled by the four humors. Accordingly, pain, like all other disease conditions, was
thought to be the imbalance of the four humors of the body: blood, phlegm, yellow bile
and black bile (Germossa, 2018; Meldrum, 2003). Medicine and pain relief was the art of
balancing the humors and this required the administration of oral medication that was
usually a mixture of opium, other herbs and an alcoholic brew of some kind (Meldrum,
2003).
Fortunately, it was also during the renaissance that researchers were uncovering
the anatomy of the living creatures, including the human body. This led to increase
understand of pain and the role of the brain and nervous system in pain perception and
sensation. The then medical community was realizing that there was both a physical and
a mental aspect to pain and that treatment should include a focus on both (Olson, 2013).
The diagnostic value of pain was also becoming increasing accepted in the practice of
medicine. But it would decades before the true importance of pain would be appreciated
and the treatment of pain would be an independent specialty in medicine.
The 17th century saw major advancement of all forms science and especially in
the areas of medicine and human biology. The prevailing understanding of physiology
was the perception of the human body as a machine that was made up of fluids and
solids. It was Descartes, the French philosopher, who put forth the idea that pain
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transmission was the blocks in the flow of the fluids of the system of nerves that ran the
machine (Germossa, 2018). Treating this pain therefore required the use of gases such as
nitric oxide or ethers, or solutions of alcohols that caused the fluids to resume their
continuous movement. Incidentally, at the end of the century a London doctor, Dr. James
Moore, was rediscovering the use of opium, as an effective post-operative pain relief
(Sabatowski et al., 2004). Meanwhile, Dr. Mesmer, a German doctor, was popularizing
the hypnotic effect of mesmerization, and in Holland, Dutch doctors were introducing
acupuncture (needling) and moxibustion (cupping), learned from their Japanese colonies,
as effective pain therapy (Sabatowski et al., 2004). Pain therapy was rapidly advancing
and brought comfort to many and facilitated medicine becoming less of an art and more
of a science.
Pain in recent history. By the beginning of the 19th century, pain was no longer
regarded as demon possession or as punishment for sin or as an imbalance of the humors.
These old ideas were all replaced by the new physiology of pain and the generation of
pain sensations. The advancement in technology provided additional insight into the pain
mechanism that positively affected the success of the pain intervention efforts. Extensive
research in the area increased the knowledge of the sensory organs and the pain pathway
and its role in the underlying illnesses. If pain was a sign of disease, then that disease
could be discovered, and the cause treated, and the pain alleviated. This era was also
marked by new insight into the nociception, the response of the CNS to painful stimuli.
And in a lab in John Hopkins, Dr. Candace Perth was the discovering the opioid receptor
(on the cell membrane) as the docking point for all the opioid molecules that initiates the
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euphoric and analgesic effects of the drug (Pert & Snyder, 1976). But before these
findings could bear fruit, the theories of pain and the drugs used in the treatment of pain
would go through several ideological revolutions.
The Modern Era of Pain Management
New theories of pain management. Managing patients’ pain is a vital
component of providing valued health care as it is essential to any quality of life
measures. As a disease, chronic pain requires an approach to the biological,
psychological, personal and social aspects, making a solution challenging (Mills,
Torrance, & Smith, 2016). Dealing with chronic pain is common to many medical cases,
with over 70% of cancer patients experiencing moderate to severe pain and (Reis-Pina,
Lawlor, & Barbosa, 2015). Also approximately 88% of patients who are dealing with
other chronic illnesses, such as cardiovascular disease, arthritis, and chronic obstructive
pulmonary disease (COPD), also experience chronic pain as their most common
comorbidity (Mills et al., 2016). However, pain management remains complicated by the
subjectivity of pain measures and the need to balance the patients’ rights to pain relief
and the risks involved in administering analgesics. But as much as pain is common to all
sentient beings, relief from pain and suffering is a cardinal principle underlying any effort
towards health and healing (Committee on Advancing Pain Research, Care, 2011).
The modern era marked the emergence of several theories to explain the nature of
pain and to guide treatment modalities. The first pain theory came in 1958 and was
known as the “Specific Theory,” suggesting that different types of pain had very different
sensory processes, each with a very specific peripheral pathway (Meldrum, 2003). This
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theory did not foster much success in the realm of pain treatment however, and it was
soon replaced by the “Gate-Central Theory” that sought to improve on the clinical and
psychological treatment of pain (Mills et al., 2016). The “Gate-Central Theory” theory
taught that even though pain had a peripheral origin, the perception of the sensation was
governed by a control trigger that was centrally located at the level of the Central
Nervous System. This theory facilitated the birth of several modalities such as the
transcutaneous electrical nerve stimulation (TENS). TENS along with massage therapy,
the application of pressure, and or electrical stimulation all proved successful in treating
various pain-related ailment (Mills et al., 2016).
Pain management as a field in medicine. By the 1960s attempts to officially
form a new ‘Pain Management’ genre in the medicine was growing among the healthcare
professionals in the field. But this would not come until the 1970s, with the formation of
the International Association of the Study of Pain (IASP) and the launch of the journal
Pain (Colliers, 2018). First the IASP was focused on establishing interdisciplinary teams
responsible for treating patients presenting with chronic pain. This patient-centered, clinic
team approach to pain proved successful by patient satisfaction reports but it would be
short lived. Unfortunately, the team approach did not survive because these pain clinics
were too expensive for the parent institutions to support, were too complicated to bill for
reimbursement, and were generally looked upon unfavorably by the insurance companies
(Colliers, 2018). Additionally, there was no backing from the rest of the medical
community as far as educating and training student doctors to perform as a member of
such a team (Colliers, 2018). Consequently, the team approach to pain management
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dissolved and regrettably the field reverted to the singular physician approach.
Chronic pain continued to widely recognized as a major medical and public health
issue, affecting 100 million Americans and costing an estimated $635 billion a year in
treatment and productivity lost (Committee on Advancing Pain Research, Care, 2011;
Nahin, 2015). But ‘Pain Medicine’ or Algiatry only become its own specialty in the last
decade or so and the several newly established professional organizations provided
inadequate training guidelines and inconsistent response to the increased demand for
related treatment service (Dubois & Follett, 2014). Over the years the effort at providing
effective pain management therapies have led to new policies, but there still exists a
significant gap between the policy and the practice in the field (Reis-Pina et al., 2015).
The shortfalls in pain assessment and treatment are the result of outdated policies,
inadequate treatment guidelines, insufficient provider training, lack of research and
provider bias and unhelpful attitudes (Committee on Advancing Pain Research, Care,
2011). Addressing gap has been an area of focus for many years and remains a challenge
for policy makers and health care professionals today.
Even though, the interdisciplinary teams of pain therapy were done away with, the
IASP survived and they continued to work towards improving the healthcare response to
pain. Pain Management now and official specialty, was a relatively new area of medicine
and was tasked with establishing standardization of the pain therapy and analgesic
administration (Tompkins et al., 2017). The work of the IASP and other organization like
it generated increased research into the pathophysiology of pain. Pain would be officially
defined as “an unpleasant sensory or emotional experience associated actual or potential
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tissue damage or described in terms of damage” (Colliers, 2018). And any pain
experience that lasted beyond the normal healing phase, which was usually under three
months, and was not associated with a chronic illness, was considered chronic (Cheung et
al., 2014).
The search for the perfect painkiller. While the field pain and pain physiology
were advancing, a related development was happening in the world of the substance used
for pain relief. Opium, the product of the poppy seed, known to be effective for pain for
centuries, was becoming the go to drug. Opium in various forms was seen as the
universal panacea and was used for everything from headaches, to small pox, to fever to
upset stomach. Instead of being smoked, opium was now eaten as a solid or drunk as the
solution Laudanum (Meldrum, 2003). Laudanum was a mixture of opium combined
cinnamon, saffron, cloves, all dissolved in wine. This solution made the administration of
exact dosage of the drug possible and therefore more convenient to use regularly and was
almost extensively among the upper class, while the lower class would line up to
purchase the now more affordable over the counter pill-form (Meldrum, 2003). The
prevalent use of opioid, in either formulation, was fast creating the problem of increasing
dependence and addiction in the Western hemisphere as it had been for China and the
Eastern hemisphere in the previous century.
While the widespread use of opium and its accompanying addiction was deemed
problematic, the effectiveness of opioid as a pain relief could not be denied. The issue for
researchers was how could the benefits of the drug be retained but without the addicting
side effects. Concerted effort resulted in chemists isolating the sleep inducing agent from
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the poppy seeds at the beginning of the 19th century and the new formula was called
morphine after Morpheus the Greek god of sleep (Reis-Pina et al., 2015). Concurrent
with this discovery, the invention of the hypodermic syringe and needle allowed
morphine’s subcutaneous administration (Meldrum, 2003). This subcutaneous form was
distinguished from the orally administered, extremely addicting form. But the positive
estimations were short lived as morphine proved to be just as or even more addictive than
other forms of opioid (Meldrum, 2003). The researchers remained optimistic however,
that a non-addicting form of opioid could be extracted, and the enquiry continued.
The research to find a non-addicting, pain-relieving opium derivative received
added impetus from the many regional and international wars taking place at the time.
The growing number of injured soldiers from the American Civil and other wars in
Europe saw many them become addicted to morphine (Berridge, 2009; Meldrum, 2003)
this loss of vitality and productivity, and in some cases loss of life that morphine
addiction brought to thousands of young men was a serious problem that needed a
solution. It was in 1865 that the Bayer Company in Germany discovered the diacetylmorphine formula that they patented with the name ‘heroin’ (Cicero, Ellis, Surratt, &
Kurtz, 2014). Like morphine, heroin was believed to be less addictive than morphine and
more effective than the opiate-based cough suppressant codeine. Unfortunately, as use of
this new formulation would reveal in time, this over the counter form of the drug, even
though a less powerful analgesic than opium, it was potently even more addicting that all
previous forms (Lembke, 2016).
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The mixed success of heroin did not damper the research efforts to find a nonaddicting formulation of opium that was just as effective at pain relief. This led to the
proliferation of many semi-synthetic and synthetic version onto the market. In the middle
of century, with lots of WWII German soldiers needing relief from their war injuries, the
effectiveness of the synthetic opioid, methadone was discovered. Originally, German
scientist created methadone to make up for the short supply of opium during the war. As
if by fortune, anecdotal evidence pointed to methadone’s long half-life and sustained
analgesic effect, that somehow appeared to suppressed cravings and feeling of addiction
(“Methadone | CESAR,” n.d.; Sabatowski et al., 2004). This eventually led to methadone
becoming the ultimate antidote to help patients successfully endure heroin withdrawal
during treatment for addiction. The popularity of methadone use grew and so did use of
the methadone maintenance therapy in clinics across the U.S (Hall & Strang, 2017;
Sabatowski et al., 2004). The effectiveness of methadone and its partial success in pain
therapy and addiction management drove the research into synthetic opiates. Meperidine
or Pethidine (known commercially as Demerol) was another synthetic opioid created in
1939 by German Chemist, Otto Eisleb (Meldrum, 2003; Yasaei & Saadabadi, 2018). His
research revealed that meperidine had analgesic properties and was versatile in its
administration properties. Whether in a syrup solution, as a subcutaneous injection or
intravenously, meperidine became the most popular choice for physicians in the mid1970s, as they prescribed it for both acute and severe pain (Manchikanti et al., 2012). At
that time, they believed meperidine to be less addicting and thus safer than morphine, but
again, later evidence pointed to the dangers of long-term use. Meperidine would become
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known to be more toxic and in 2003, it was removed from the WHO List of Essential
Medicines, but alarmingly, it remains the most widely used opioid analgesic during labor
and delivery (Yasaei & Saadabadi, 2018).
Fentanyl, another synthetic opioid, was the next opium option on the market,
created by an American chemist Paul Janssen in 1960s (Stanley, 2014). Fentanyl is
widely used legally in healthcare for both analgesic and anesthetic purposes, but it is also
very popular as an illegal, recreational drug. It is 100 times more powerful than morphine
and is currently the most widely used of all the synthetic opioids, while many of the
illegally produced analogues are 100 times stronger than fentanyl itself (Paparella, 2014).
Fentanyl can be administered in many forms, including intravenously and intrathecally.
Intravenously it is mixed with either propofol for general anesthesia, or benzodiazepine
during oral surgery or endoscopy. Alone it is used in the treatment of chronic pain such
as that of cancer patients or chronic low back pain. Intrathecally, fentanyl’s chemical
properties make it a suitable for epidurals, as well as transdermally, in time-release skin
patches (Paparella, 2014). Orally, as sublingual lozenges (Oral Transmucosal Fentanyl
Citrate or OTFC) or as lollipops, or nasally, as sprays or inhalers are other modes by
which this drug can be administered (Paparella, 2014).
Unfortunately, the pharmaceutical fentanyl is one of the opiates that finds its way
onto the black market and combined with the illegal manufacture and distributions of the
analogues, makes it a major public health nightmare. Fentanyl can be smoked, snorted,
injected or ingested and because of the similarity of its effects to heroin, it is sold,
deceptively as heroin or oxycodone, but is so much more lethal (Stanley, 2014). The
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FDA issues warnings in 2005 and again in 2007 public health advisory, warning about
the dangers of Fentanyl use, particularly the patches, which “doctors were inappropriately
prescribing, and patients were incorrectly using” (Stanley, 2014). During that time, the
Insurance Company attempted to respond to this national public health crisis by requiring
physicians to have precertification and instituting limits on the quantity they could
prescribe. However, the situation persisted and in 2016, 20,100 persons (half of opioid
related deaths) died from an overdose of fentanyl, which was a 540% increase from the
number in 2013 (Manchikanti et al., 2012).
Other semi-synthetic opioids were continually being placed on the market.
Oxycodone or oxycontin (known commercially as Percocet), can be administered as an
immediate release or controlled release, intramuscularly or intravenously, combined with
paracetamol (acetaminophen) or and with the nonsteroidal anti-inflammatory drugs
(NSAIDs), aspirin or ibuprofen (Mazer-Amirshahi et al., 2016). Oxycodone, like the
many opioid alkaloid, is derived from the opium poppy seed, and was synthesized in the
1917 in Germany after Bayer had stopped producing heroin. It is created by industrial
conversion from thebaine, an opiate alkaloid, and acts as a moderately analgesic, slightly
more potent than morphine and due to its mild euphoric effect, it is one of the drugs
contributing to the opioid abuse epidemic (Puja Seth, Rudd, et al., 2018). Other forms of
opioid include codeine, the popular pain killer and cough suppressant, as well as
hydromorphone, buprenorphine, hydrocodone, and hydromorphone.
As the research were going on laboratories across the world to find the best
chemical compound that could relieve pain and was not addicting, others were trying
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something different. Much of the earliest history of pain relief is closely tied to use of
opium as it served as both as a psychoactive effect and the analgesic properties. Other
non-opioid pain-killers included ether, chloroform, used extensively during childbirth and
for dental surgeries in the 1800s (Meldrum, 2003). In the early 1900s, morphine and
heroin were believed to be the answer to the pain dilemma as it seemed to relieve pain,
improve the patients’ quality of life, while not present any apparent side effects. But
those side effects were showing up and the picture was gloom. There was the suppression
of respiratory activity, the mental depression and low mood and with extend use came the
abuse and addiction. But opium was always remained at the forefront and has caused a
concerted effort to maximize its potential for good while minimizing it’s the risk of its
side effects.
How opioids became the drug of choice. The field of pain management has
undergone several changes over the years and the relief of pain has evolved. The changes
have been driven by the need to find better solutions that meet the needs of patients and
help the healthcare workers be more confident in administering them. In the early 1990s,
there were reports of inadequate pain management and unnecessary suffering caused by
under-treatment of patients’ pain and this prompted a review of the practices followed by
changes in pain management policies (Agency for Health Care Policy and Research,
1992; Dubois & Follett, 2014; Mills et al., 2016). To curtail the reports of undertreatment, more proactive measures in pain treatment were instituted as the existing
procedures were deemed not effective enough (Cheatle, 2015). This lead to the
replacement of the paracetamol (acetaminophen) and non-steroidal anti-inflammatory
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drugs (NSAIDs) with the controversial opioid based analgesics (Morone & Weiner,
2013).
Despite the history of addiction risk associated with opioid, its use as the go-to
prescription drug in pain management was growing. The idea of possible under-treatment
combined with the new more effective, faster-acting opioid drugs and the aggressive
marketing by the pharmaceutical companies resulted in physicians replacing their opioid
phobia with an over confidence in the drug (Kata et al., 2018). A few experts were
touting opioids as safe and non-addicting and the physicians were prescribing them major
doses of them to everyone who complained of pain (Daum, Berkowitz, & Renner, 2015).
The newer longer-acting opioid formulations with improved bioavailability and
aggressive marketing by the pharmaceuticals, led physicians to give up their opioid
phobia and replace it with a less retrained prescribing habits (Sehgal, Manchikanti, &
Smith, 2012). Although not much was known about the risk involved in long-term use of
opioids or the adverse effects of heavy dosages, the drugs proved effective and this
combined with other patient and physician factors resulted in increased opioid
prescriptions being dispensed (Juurlink & Dhalla, 2012). The situation soon resulted in a
dramatic upsurge in opioid prescriptions, with the rate doubling twice by the end of the
decade (Cheatle, 2015). But this development did not happen in a vacuum and other
changes in the field would precipitate the opioid epidemic.

41
Pain as a fifth vital sign. It was during the changes in drug choice, that another
important policy regarding pain management was taking place. In the 1995, the American
Pain Society was successful in getting “pain” to be classified as another of the vital sign
that should be routinely monitored in a medical setting (Morone & Weiner, 2013;
Sedeno, 2015). Pain became the 5th vital sign, after “body temperature”, “pulse rate”,
“respiration rate (rate of breathing)”, and “blood pressure”. As a result, pain reporting
became more common, and this drove the increased prescription of analgesics. One of
those landmark changes was the declaring of pain as the 5th vital sign. Unfortunately,
making pain a 5th vital sign had some negative consequences. The Numeric Rating Scale
(NRS) was being used to report the level of pain patients were experiencing. However,
these patients were reporting pain because they had to, even when there was no real
suffering being endured as a result of it (Morone & Weiner, 2013). Additionally, the
medical professionals were not adequately trained nor were they offered sufficient faceto-face time to properly assess the nuances of the pain that the patients were reporting
(Morone & Weiner, 2013).
Making pain the fifth vital sign was yet another factor driving the increased rate
of opioid prescription. In addition to the NRS which measures the severity of sensation,
pain can be classified based on additional features such as frequency of occurrence,
duration of discomfort, response to treatment or other changes, and the presence of any
incapacitating consequences (Committee on Advancing Pain Research, Care, 2011). The
distinction between acute pain and chronic pain was being blurred and while acute pain is
a vital sign, chronic pain is its own distinct entity. Other important distinctions were
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overlooked, such as whether the pain was nociceptive (tissue damage) or neuropathic
(nerve damage), which each require a different treatment approach (Mills et al., 2016).
According to the International Association for the Study of Pain (IASP), the focus
is on the cause when dealing with acute pain, but for chronic pain it is all about the
reducing the effect and improving quality of life (Mills et al., 2016). But physicians,
pressed for time, resorted to ubiquitous opioid prescription for anyone reporting pain
symptoms. This behavior only added to the growing problem of an overabundance of
opioid prescription and a subsequent increase in opioid abuse and addiction.
In 2000, the new pain management laws put in place by The Joint Commission:
Accreditation, Health Care, Certification (TJC) reinforced the right of each individual to
pain relief and the obligation of doctors to administer pain medication to patients
presenting with pain complaints (Manchikanti et al., 2012). The facilitated increase
support for not for the use of opioids but for the use of large doses. This also motivated
the aggressive marketing of the drugs along with misinformation about their efficacy and
safety. This led to dangerous assumptions on the part of prescribing physicians and
perilous situations for patients being treated.
The next decade saw the rise in the use of prescription opioids as they were now
believed to be safe as there was little research and therefore little evidence of its addictive
propensity. In the age of the “prescription culture” where drugs were seen as the solution
to most medical issues, opioid became more popular among oncologists in the long-term
treatment of cancer patients’ pain as well as others suffering from moderate and severe
chronic pain episodes (Colliers, 2018). This rise was driven by the heavy campaigning of
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the pharmaceutical companies that lasted almost two decades. Opioids were not only
promoted as safe and effective, they were promoted as have a high cost-benefit ratio for
the patients, an idea endorsed by the major insurance carriers. Exacerbating the epidemic
of opioid use was the work of drug-traffickers who were able to traffic cheap versions of
the drug and their many analogues. The effect of making pain the 5th vital sign combined
with the other negative forces in the society at the time conspired to exacerbate the
brewing opioid addiction crises.
Drug Addiction and the Opioid Epidemic
The birth of the opioid epidemic. The turn of the century saw opioids becoming
the most common analgesics in pain management therapy, sustained by their
effectiveness in treating all types of pain. Opioid is an effective analgesic that also
produces the mind-altering effect of euphoria and it is this effect that can lead to
addiction and abuse. People start off using the drug for relief from pain, but eventually
continue after the pain is gone− because of compulsion; seeking feelings of reward; or for
diversion from their life (Gugelmann, Shofer, Meisel, & Perrone, 2013; Murthy, 2016).
In most cases the illicit use of the drug started with a prescription for a non-cancer related
pain, usually a high-dosage prescription of an extend release version of the drug (Sehgal
et al., 2012). This unfettered prescribing, despite the absence of evidence of its long-term
effectiveness and conflicting physicians’ guidelines, resulted in many cases of opioid
misuse and abuse (Cheatle, 2015; Manchikanti et al., 2012).
Over the last two decades, the frequent and wide spread use of opioid drugs
caused many to ignore the emerging signs of adverse effects and to falsely believe in its
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safety at any dosage. By the year 2003, prescription drugs abuse, a majority of with
involved opioids, was now greater than that for illicit drugs like, methamphetamine,
cocaine and heroin (International Narcotics Control Board, 2006). Later research on the
efficacy and risks involved in long-term use would report on− the potential for adverse
effects, the low to moderate effectiveness, and the increased probability of overdose as
well as the abuse associated with prescriptions for high dosage and long-term use of these
drugs (Cheatle, 2015). But in the meantime, many physicians were finding opioid
prescribing to be a quick and convenient solution to the many challenges faced in the
field of pain management (Lembke, 2016).
By 2010, opioids, which were previously restricted to use for severe or chronic
pain, was now used for all types of pain regardless of intensity or duration. Opioid
prescriptions were first introduced for the treatment of the severe pain associated with
major surgery or trauma, but now it had become the mainstay for other pain symptoms as
well (Reis-Pina et al., 2015). But now doctors everywhere were prescribing high doses of
opioid for long-term use in the treatment of severe as well as moderate pain, but there
was little knowledge about the actual threshold for these drugs or the risks involved in
going beyond said threshold (Cheatle, 2015). The rise in the rate of opioid prescription
and the sale of the opioid pharmaceuticals would see an increase of 400% between 1999
and 2010 (CDC, 2011). It is the excessive prescription of opioids, in the form of chronic
opioid therapy (COT) and for chronic non-cancer pain (CNCP), that led to the explosion
of opioid addiction and the many ill effects in the society. The increase in long-term
opioid use and COT together with the liberalizing of the laws governing its use in NCP
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over the turn of the century culminated in an increase in abuse, addiction and death from
the misuse of the drug (Cheung et al., 2014). This errant prescription behavior fueled by a
lack of knowledge and a dearth of education or training was believed to be the “root
cause of the opioid epidemic” was to taking hold among the community (Barnett et al.,
2017).
The challenge of defining drug addiction. Documenting the extent of the opioid
epidemic has always been complicated by the absence of any universally accepted
characterization for addiction. Those attempting to measure the prevalence of abuse and
addiction of any analgesic has had many trials, as standardizing a diagnosis of abuse or
even misuse in field of pain management is almost impossible, even for the pain experts
(Mills et al., 2016). The lack of diagnosing regulations along with the inconsistency in
defining abuse, results in challenges to measuring the extent of the problem (Sehgal et al.,
2012). This lack of uniformity is reflected in the reports of rates of abuse, varying from
1% to as much as 40% across different research findings (Cheatle, 2015). A lot of work
has gone into documenting and reporting on the epidemiology of the opioid epidemic,
and much has been reported but some uncertainty remains.
In an attempt to resolve the uncertainty relative to diagnosing addiction, several
agencies got involved. At the beginning of 2001, the American Pain Society (APS), the
Society of Addiction Medicine (SAM), and the American Academy of Pain Medicine
(AAPM) joined forces to develop a much-needed working definition for addition, for
those in the pain management community. This group defined ‘addiction’ based on
various signs including- subjects inability to control their use of the drug; continued use
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even after the drug causes obvious harm to the user; using the drug compulsively; and
craving the drug for reasons other than to relieve pain (Cheatle, 2015; Sehgal et al.,
2012). But this did not simply things, as all the signs can also be seen patients dealing
with other physical ailments and comorbidities other than those for which they were
prescribed analgesics (Von Korff et al., 2016). This combined with the issue of drug
tolerance and drug dependence being common in normal pain management therapy
makes any official diagnosis abuse and addiction difficult (Hughes et al., 2016).
Other agencies, recognizing the need for standardization, decided to join in the
effort to try and formalize a definition for addiction. The Analgesic, Anesthetic and
Addiction Clinical Trials, Translations, Innovations, Opportunities and Networks
(ACTTION), panel of experts in the field, came together to put forth recommendations
for defining abuse and monitoring prescriptions. In their published report, inappropriate
use of the drug was defined as misuse and abuse was defined as intentional use of the
drugs for the psychological effect (Cheatle, 2015; Han et al., 2017; Vowles, 2015).
Additionally, the Statistical Manual of Mental Disorders (DSM)-Fourth Edition included
tolerance and dependence along with the behavioral abnormalities in their definition of
chronic opioid use (Sehgal et al., 2012). But the 2013 version of the DSM-Fifth Edition
changed the Substance Use Disorder category supposedly to simplify diagnosing abuse.
The DSM combined abuse and dependence into one and this new category had three
levels of severity- mild, moderate and severe (DSM-5 quoted in Cheatle, 2015). They
then made tolerance and withdrawal relevant only in the cases where there was no
licensed clinician, but this did not simply the issue. The DSM-IV version of abuse
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includes the terms ‘tolerance’ and ‘physical dependence’, both of which are inevitable
consequences of chronic opioid use. The APS definition ‘compulsion’ and ‘craving’,
which are also difficult to assess as they can be caused by real underlying need for pain
relief (Sehgal et al., 2012). There were now several working explanations but no
universally accepted definition of addiction.
The many editions issued as the definition of pain by the pain ‘experts’ proved
counter to the needs of those dealing with patients as well as those attempting to
document the extent of the problem. For example, the rate of abuse based on the more
sensitive DSM-5 did not differ much from that using DSM-4, and the rate of misuse and
abuse from systematic reviews of several studies, using ACTTION guidelines, varied
between 1 and 81% across 38 studies (Cheatle, 2015). Although these studies included a
variety of clinical settings, different patient populations, and an assortment of pain
conditions, the variation indicated the need for additional work on the consistency of the
approach. Insufficient or inadequate standardizing of abuse and addiction definitions
made determination of prevalence among patient population a persistent issue. This
discordance makes it challenging for healthcare providers and regulatory forces to come
to a consensus on the nature and extent of the problem. To devise appropriate treatment
plans to deal with the disorder of addiction and reduce the burden on the society better
standards based on evidence-based research is needed (Murthy, 2016). Despite the lack of
precision to the existing data, the opioid epidemic is real and that it demands a solution.
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The height of the opioid epidemic. Despite the inaccuracies, there are many
estimates that provided an insight into the extent of the developing opioid epidemic. At
the beginning of the decade there were 15.3 million adult Americans using opioids, and
that number would rise to 23.8 million in 2005 (Sites, Beach, & Davis, 2014). Over the
five-year period from 2006 to 2011, morphine use went from 1.82 mg/person to 61.66
mg/person (Cheung et al., 2014). The true incidence was believed to be higher, but an
estimated 26% of the COT outpatients and 20% of Medicaid patients were abusing
opioids (Sehgal et al., 2012). The prevalence of opioid abuse went from 4.1% to 4.6%
among young adults during the years 2002 to 2007, with overdose fatalities at 15.9% for
males and 11.2% for females (Rudd, Aleshire, Zibbell, & Gladden, 2016). By 2009, there
were over 7.0 million (approximately, 2.8% of the population) addicted to opioids and
this was in increase from the 6.2 million counted in 2008 (Sehgal et al., 2012). In 2010,
60% of all drug overdoses were from prescription drug and 75% of those were opioid
analgesics (National Survey on Drug Use and Health, 2013). The problem of opioid
abuse was growing, fueled by the growing rate of opioid prescriptions being dispensed.
As rate of opioid prescriptions escalated, rate of abuse of the drug continued to
rise. This reflected an increase in the number of medical emergencies related to
prescription drug abuse by 183% from 2004 to 2011 (U.S. Department of Health and
Human Services, 2013). By 2012 there were 4.9 million users reported abusing opioids,
while some 35% of those in chronic opioid therapy eventually developing an opioid use
disorder (Cheatle, 2015). That same year 488,004 patients presented to the emergency
room (ER) with opioid overdose and another 180, 004 were treated for using opioid for
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non-medical reasons (Cheatle, 2015). Moreover, the abuse of prescription drugs is also
tied to other drug use, as one study found that 80% of all heroin users previously used
prescription medication (Muhuri, Gfroerer, & Davies, 2013). In 2015, the National
Survey on Drug Use and Health (NSDUH) survey determined that prescription
psychotherapeutic drugs, mainly opioids, were second only to marijuana as the most
prevalent illicit drug (Hughes et al., 2016). The opioid epidemic was in exploding in the
society and it was contributing to other issues of drug abuse.
The opioids involved in opioid abuse had some distinct characteristics. The
extended release and the immediate release forms of hydrocodone and the oxycodone
account for 75% of the abused prescription drugs (Hughes et al., 2016). Fentanyl,
hydromorphone and morphine, the more potent µ-opioids, made only a small portion
(5%) and methadone was the street drug of choice in over 70% of the case, versus the
30% divided among OxyContin or Vicodin or Percocet (Sehgal et al., 2012). The sale of
morphine increased by 222% and that of methadone by 1293% between 1997 and 2007
(Manchikanti et al., 2012). Unfortunately, almost a decade ago, the reports already
indicated that Americans use 66% of all the illegal drugs on the planet, consuming 80%
of all the opioids and 99% of all hydrocodone (Manchikanti et al., 2007). Untangling the
web of opioid drugs is one of the most difficult aspects of this epidemic.
Added to the many problems caused by the opioid epidemic is that of drug
diversion. Much of the drugs being abused are obtained originally from a prescription but
ends in the hands of friends or relatives for whom it was not prescribed. Over 56% of all
opioids used non-medically and 50% of all used in the overdose fatalities are classified as
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diverted drugs (Sehgal, 2002). These are obtained from elderly pain patients, from those
who engage in doctor shopping or bought illegally on the black market. Unfortunately,
the abuse of prescription opioids is considered the gateway to other drug addiction,
namely heroin (Beaudoin et al., 2018; Murthy, 2016; Poon & Greenwood-Ericksen,
2014). Opioid abuse is linked to other illegal drugs as well as the use of legal drugs like
cigarettes and alcohol, all of which makes it difficult to design dissect the problem and
design interventions.
The burden of the opioid epidemic. Opioid abuse was causing a great deal of
health problems and this took an exorbitant toll on the cost of health care. A patient who
was also an opioid abuser was costing 1.8 times that of a non-abuser, $16,000 versus
$1,800 and the total cost of the opioid epidemic in 2001 was $8.6 Billion in healthcare
cost, work place earning lost and the criminal justice system expenditure (Sehgal et al.,
2012). By 2007, the cost was $55.7 Billion and the annual cost for each opioid abuser
was now $20,546 (Meyer, Patel, Rattana, Quock, & Mody, 2014). There is also the
disability cost associated with opioid abuse as chronic opioid therapy (COT) is associated
with an increase in disability and added financial expenditures. The cost of care for
patients using the opioids are three times more likely to need surgery and on average
require 69 more days of disability and workers compensation that those not using opioid
(National Academies of Sciences, Engineering, and Medicine, 2017; Florence, Luo, Xu,
& Zhou, 2016). Both opioid use and opioid abuse was costly to the society and to the
healthcare budget.
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In addition to the financial burden of the opioid epidemic, there were certain more
direct dangers associated with the use of these drugs. Opioids can cause opioid-induced
hyperalgesia (OIH), a condition of patient becomes even more sensitive to the painful
stimuli and experiences more painful sensation when taking the medication than when
not taking it (Cheung, 2014). Opioids are also known to cause respiratory depression or
hypoventilation, which can result in respiratory arrest and eventually death if not treated
in time (Reis-Pina et al., 2015). Opioids are also associated with an increase in suicide
rate, increase in overdose, increase in crime rate to users (National Center for Health
Statistics, 2015a). While opioids are an important and effective analgesic but there are
many dangers associated with this class of drugs, unfortunately the former is better
known than the later.
Opioid-related morbidity and mortality. Poisoning is the leading cause of
injury death, and 90% of these poisonings are from the misuse/abuse of prescription
drugs, mainly opioid pain relievers (OPR) (National Center for Health Statistics, 2015a).
Between the years 1999 -2011, the opioid prescription related (OPR) deaths almost
quadrupled, going from 1.4 to 5.4/100,000, and although the rate slowed around 2006, it
started rising again in 2011 (Cheatle, 2015). The increase in OPR death rate was seen
across all age, all racial groups, and urban areas in multiple states, accounting for two
thirds of drug overdose death (Seth, Scholl, Rudd, & Bacon, 2018). States like NH, OH,
WV had the highest death rates, some prescription OPR deaths higher than that for heroin
(Vivolo-Kantor et al., 2016). The first wave of prescription OPR deaths occurred in 1990,
the second in 2010 with mostly heroin deaths, and the third wave in 2013, mainly from
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the synthetic opioid illicitly manufactured fentanyl (IMF) (Vivolo-Kantor et al., 2016).
The IMF accounted for 30.5% of all drug overdose deaths and 45.9% of all OPR deaths,
representing a 100% increase from 2015 (Seth et al., 2018). Figure 4 includes
comparative data on drug overdose deaths overall and deaths specifically involving
opioids.

Figure 4. Drug overdose deaths (P Seth, Scholl, Rudd, & Bacon, 2018).
The epidemic of drug overdose is growing, and this is evidenced by not just the
worsening opioid-related death rate but specifically the deaths from opioid analgesics
(OA) overdose. Like the increase in opioid prescriptions, deaths caused by unintentional
prescription opioid overdose has risen sharply over the past two decades and have
surpassed deaths from heroin and cocaine combined (Substance Abuse and Mental
Health Services Administration, 2016). The rate of drug overdose increased 137%, and
200% for OA overdose, including natural and semisynthetic opioids (Rudd, 2016).
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Between 2013-2014, the age-adjusted increase for natural and semisynthetic OA, heroin,
synthetic OA (fentanyl) OA were 9%, 26%, 80% increase, respectively (Rudd, Seth, et
al., 2016). Over half a million died from opioid overdose between 2010 and 2014, mainly
opioids (prescription pain reliever and heroin), but 61% died 2014 alone making it the
deadliest year since (Rudd, Seth, et al., 2016). Unfortunately, of the 63 632 persons who
died of drug overdose in 2016, 66.4% were OA overdose, most of which were IMFs
(Seth, 2017). The increase in prescription OPR and the surge in IMF availability,
contributes to this growing dilemma that continues unabated despite many intervention
strategies.
In the past, reports of deaths caused by an opioid overdose usually include both
prescription opioids and illicit opioids, thereby inflating the reports with no distinction
made between the sources in the death certificates or the coroners’ reports. For example,
in 2016, that number was 42,249 and included morphine and oxycodone (prescription)
and heroin (illicitly manufactured fentanyl or IMF and heroin), but half of which was
believed to involved IMF (Seth, Rudd, Noonan, & Haegerich, 2018). Combining the
numbers hid the fact that the prescription drug-related deaths had not changed much, and
the increase was mainly due to the sharp increase in the use of synthetic opioids, mostly
IMF (both prescription and illegal manufacture). However, new procedures put in place
by the CDC allows for improved distinction between the prescription and the illicit drugs
involved in overdose fatalities (Seth et al., 2018). Effective prevention strategies depend
on accurate targeting of the correct source of the problem, e.g., high-risk prescribing vs
illicit drug availability. It is believed that educational guidelines and prescription
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monitoring as well as stricter enforcement are an integral part of solving the epidemic.
Partnership between public health, medicine and law enforcement are all essential to the
success of the response.
Screening and the opioid abuse risk factors. Identifying the risk factors
associated with potentially abusing opioid or developing an addition to the opioids is
critical to the response to this public health dilemma. Although there are many screening
tools, their use is not mandatory, and none have been validated for generalizable use
across different sectors of the country. Most of the tools are made up of a paper survey to
collect medical and personal history and a one-on-one interview to assess mental,
physical and psychological state (National Center for Health Statistics, 2015a). The most
recently published study that examined the link between ED prescription and opioid
abuse was conducted using the database of a commercial insurer. Researchers wanted to
do a comprehensive to study the factors that increase the risk of opioid abuse and
dependence and used the database of a larger commercial insurer (Cochran et al., 2014).
The study evaluated all the 2,841,793 patients who filed at least one opioid claim
between 2000 and 2008, of which 2,913 were diagnosed with an opioid abuse disorder
diagnosis within subsequent two years (Cochran et al., 2014). Young males who had a
history of opioid prescription− combined with a history of psychiatric disorder
(depression or anxiety), plus a lengthier prescription supply, who were also using other
medications, and had used several pharmacies for filling their opioid prescriptions− were
the ones more likely to develop an OUD (Cochran et al., 2014).
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The collected patient data, along with the prescription guidelines, should be used
to guide the providers’ prescription decisions. This data collected should be used to
assess the patients’ suitability for opioid prescription and to determine the dosage.
Subsequent follow-up assessments should be used to manage the patients’ response to the
medication and monitor any tolerance or dependence issues (National Center for Health
Statistics, 2015a). The APS and the AAPM recommend a through history and physical
exam and that the prescribing of opioid should be on a trial basis initially along with
informed consent of the patient (National Academies of Sciences, Engineering, and
Medicine, 2017). The dosage should be low to start, and the follow-up should consist of
careful patient monitoring and any increase in dosage should be gradual dose titration
(National Academies of Sciences, Engineering, and Medicine, 2017). But all these are
recommendations and should be amended based on the unique situations that present and
the skill of the provider of making the appropriate prescription response.
Using data from the published literature, researchers have attempted to classify
the various risk factors involved in opioid overdose. Several factors have been identified
and they include socioeconomic status, demographics, environmental factors (Beaudoin
et al., 2018). Additionally, personal factors such as family history of drug abuse, genetics
(the type of opioid receptor), history of alcohol and substance abuse, psychopathology
and other pain tolerance and drug dependence factors (Pomerleau et al., 2016) (Weiner et
al., 2013). Possession of any three, of the aforementioned risk factors, should be
considered high risk for opioid abuse and care should be taken before prescribing opioid
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to such a patient (Murthy, 2016). The factors and the associated screening tools are
available, but they are use is still not widespread.
One group of researchers undertook a systematic review of the literature to assess
the major factors for opioid abuse across North America. The three main category of risk
they identified were: the behavior of the user; the patient’s environment; and the behavior
of the prescriber as having an influence on the rate of opioid-related mortality (King,
Fraser, Boikos, Richardson, & Harper, 2014). Additionally, the role of the provider’s
prescribing pattern with− respect to type of opioids (oxycodone, methadone, etc.), the
dosage of the prescription, the duration of the prescription− were also key (King et al.,
2014). The user-related factors included: how the opioids were obtained (diversion,
pharmacy shopping, polydrug, etc.) and the patient’s sociodemographic characteristics
(race, gender, age, history of substance abuse). Rates of mortality were higher in nonHispanic, White males, American Indian/Alaska natives and middle-aged persons living
in rural areas (King, 2014). Even though other contributing environmental factors
included SES, geography, PDMPs and policies and media coverage also played a role,
race/ethnicity was determined to play a major role.
Most of the prescribing guidelines that were put in place at the height of the
epidemic and some were more detailed than others. Physicians were advised to conduct a
thorough personal history of the patient prior to prescribing anytime of opioid.
Knowledge of the patient’s personal history, their family history, the criminal and
incarceration history or any event trigging a post-traumatic stress disorder type reaction
were deem critical by some (Poon & Greenwood-Ericksen, 2014). Also important were
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health issues such as whether they were smokers or alcoholics as co-occurring substance
abuse was important (Sinnenberg et al., 2017).
Assessing the mental state of the patients is also very important as comorbid
psychotherapy plays a role in addiction, as a history of mood disorder, depression and the
use of psychiatric medication, all increase the patients drug misuse index (DMI) (Sehgal
et al., 2012). Also common among abusers is a diagnosis of sexually transmitted diseases
such as hepatitis A, B, or C or human immunodeficiency virus, acquired
immunodeficiency syndrome (HIV) (“Opioids and methamphetamine: a tale of two
crises,” 2018). These factors can be complicated by the patient’s level pain tolerance of
the degree of personal impairment, limitation, or disability being caused by their pain
(Reis-Pina et al., 2015). Though, this list is not exhaustive, but it demonstrates how
many factors can play a role in a patient’s propensity towards abuse once prescribed an
opioid.
Prescription Opioids and the Variation in Prescription Rate
The role of prescription opioids. Opioids, a type of analgesic made from the
opium plants, and the prescription forms are the most powerful prescription for relieving
pain. The prescription or legal opioids include hydrocodone, oxycodone and morphine
and the illegal drugs include heroin and illicitly manufactured fentanyl (IMF). Although
the prescription drugs are effective analgesic, they like the illegal ones, have psychotropic
euphoria producing effects that can encourages physical dependence and possibly of
addiction in some users (Sehgal et al., 2012). Use of these prescription opioids continue
to increase despite the lack of supporting data and despite the increasing evidence about
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opioid addiction and death due to over dose (Cheung et al., 2014). The increase in
prescription opioid results increased exposure, it has been paralleled by an increase in
opioid abuse.
An earlier study in Utah in 2011, was designed to investigate the role of
prescription opioids in the opioid epidemic. The study was commissioned by the chief
medical examiner to determine the extent to which prescription drug patterns of opioid
played a role in the opioid crisis and whether the findings corroborated with the data from
the medical examiner on death certificates (Porucznik et al., 2014). Medical records that
included various administrative databases such as vital statistics, medical examiner
records and emergency departments and state prescription registry were used (Porucznik
et al., 2014). The researchers also intended to use the findings to design intervention
programs that would help reduce the burden that the crisis was having on the state’s
medical care system. The analysis of the data, though possibly prejudiced by the data
availability and ascertainment bias, confirmed the suspected link. The study found an
increase in opioid prescription rates that correlated with an increase in opioid exposure to
the population over the same period (2004 to 2010) and this increase also paralleled an
increase in adverse events such as drug-related fatalities (Porucznik et al., 2014).
Regrettably, the authors stated that more research was needed to determine the userrelated risk factors on which effective intervention can be based and did not include the
provider-related risk factors involved in streamlining the related prescription rate.
The link between prescription opioids, though not straightforward, has been
verified by various published articles. One such study conducted by the NSDUH revealed
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that 22.6 million Americans (8.9%) were illicit drug users in 2010 (Manchikanti et al.,
2012). During that same period, 7 million were abusing marijuana, 5.1 million were
abusing pain relievers (Manchikanti et al., 2012). Of those that were abusing pain
relievers, 17.3% originally obtained the opioid from a prescription (Manchikanti et al.,
2012). The following year, 2011, 238 million prescriptions for analgesics were written
and 136.7 million (over 57%) were for the opioid hydrocodone (Manchikanti et al.,
2012). Sadly, 60% of the opioid related deaths were from standard prescriptions, and
most were for morphine of over 100 mg per day, the other 40% of the deaths were from
opioid received illegally, from “multiple prescription, doctor shopping and drug
diversion” (Manchikanti et al., 2012).
Four years later a cross-sectional study was conducted to assess the association
between prescription opioid and opioid abuse. This determined that over 37% of the U.S.
population had used prescription opioids that previous year, with some 11.5 million
reported misusing the drug, and almost 2 million developing an opioid use disorder (Han
et al., 2017). The study also revealed that most of those who abused the drug were
uninsured, underemployed, had a low income, and a history of mental health issues (Han
et al., 2017). The most important insight from this study was the fact that among those
who misused opioids, 59.9% did not have a prescription for the drug at the time and
obtained it free from friend or relative who did (Han et al., 2017). Similar evidence
implicates the deviant opioid prescription patterns that must be addressed, as they can
make opioids available for misuse and abuse and contribute to the opioid epidemic.

60
Addressing the trend in opioid prescription and zeroing in on the prescription in
the ED, a study using research consortium data was conducted in 2014. The researchers
wanted to compare the data with the previous survey extrapolation findings and used a
national sample of ED patients that included 1.4 million visits across 19 EDs over a oneweek period (Hoppe et al., 2015). Of the 1.4 million, 27,516 were evaluated, and 17%
(3,284) of those were discharged with an OPR prescription (Hoppe et al., 2015). The
most common conditions were back pain (10.2%) and abdominal pain (10.1%), most
frequent OPR being oxycodone (52.3%), more than 99% of which for the immediate
release form (Hoppe et al., 2015). The results reinforced the previous findings and
confirmed the upward trend in prescription rate even after national prescription
guidelines were disseminated.
Race/Ethnicity and opioid prescription rate. Identifying the risk factors
involved in opioid prescription rate is critical to responding to this crisis. In the
emergency setting it is difficult to assess patient’s potential for drug abuse and ED
providers are required to make quick decisions without compromising patient care.
Studies have indicated that sometimes these decisions are based on the providers’
subjectivity and certain factors play a role. Among the many factors, a patient’s raceethnicity, as with other areas of medical care, is foremost in the disparity that exists in
receiving opioid therapy (Joynt et al., 2013; Knopf, 2017; Tamayo-Sarver et al., 2003).
One study found significant racial-ethnic differences and they may reflect unconscious
provider biases, with providers being less conservative in their opioid prescribing with
non-Hispanic Whites than with non-Hispanic Blacks (Singhal et al., 2016). As far as the
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findings were concerned, when it comes to prescription opioids, race matters.
In a nationwide study that looked at pain management in the ED confirmed the
racial-ethnic disparity. The study restricted the patient diagnosis to nontraumatic acute
abdominal pain according to a uniform ICD-9 definition and included all adults in the
2006-2010 NHAMCS database (Shah et al., 2015). A risk-adjusted stratified analysis of
the modulators including, ED wait time, number of diagnostic tests, and subsequent
admission, was conducted to determine the relationship between race and analgesic in the
ED. The study found that Blacks and other minorities had a 22-30% lower odd of
receiving analgesics compared to whites and the difference in odds was greater for 18 to
21 age groups (Shah et al., 2015). Interestingly, not only were more Whites being
prescribed opioids, they dying by greater numbers from opioid overdose.
Race plays a major role in the discrepancies in the unfolding of the response to
the opioid crisis. The decline in the life expectancy of Whites started a few years after the
FDA approved OxyContin (1998) and TJC made pain the fifth vital sign (2000) and
opioid-related mortality among Whites was found to be three times that of blacks by 2003
(Case, Deaton, Cutler, Skinner, & Weir, 2015). As the drug overdose dilemma caused the
life expectancy of U.S. Whites to decline, research confirmed the connection to the
disparity in marketing and access to the drugs. Opioid manufacturing and dispensing was
controlled in such a way that was more likely to be to White patients than non-Whites
(National Academies of Sciences, Engineering, and Medicine, 2017). Furthermore, laws
were put in place that distinguished crack cocaine from its powder form and
differentiated the abuse of prescription opioids addiction from that of the heroin addiction
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(Case et al., 2015). When news of the mostly middle-class, white-color opioid dependents
surfaced, the prescription programs and the naloxone and buprenorphine clinics were the
response versus the high rate of arrests for illegal heroin use (Case et al., 2015).
According to Cheung (2014), environmental exposure was the number one risk factor for
potential abuse, emphasizing the need for careful monitoring of the prescribing practices
surrounding opioid medication. But even as more information of this type was became
available, the rates of abuse continued to increase and the racial disparity among those
affected persisted. Figure 5 includes age-adjusted opioid analgesic poisoning rates, by
race and ethnicity.

Figure 5. Age-adjusted opioid analgesic poisoning rates, by race and ethnicity (CDC,
2011).

63
Socioeconomics and opioid prescription rate. Patients in a lower
socioeconomic (SES) have a have a greater risk for many medical issues. These patients
are less like to receive proper health care, due in part to limited access to primary care,
low employment and relatedly inconsistent insurance (Hudley et al., 2014). SES is
another one of the factors contributing in the disparity of that exists in administration of
pain treatment. A qualitative, one-on-one interview study indicated that providers’
perceptions of patient’s SES and attitudes towards those in a lower SES affects their
treatment of their chronic pain patients (Hollingshead, 2016). These pain management
decisions were influenced by the health insurance and other signs of financial constraints
(Hollingshead, 2016). The prescribers expressed suspicion towards these patients as drugseekers and believed that being in a lower SES puts patients at greater risk of opioid
abuse (Hollingshead, 2016). A comprehensive study using PubMed, CINAHL and
PsycArticles databases conducted a similar study and confirmed biases against those in
lower SES, which limited their access to opioids and other analgesics (Maly & Vallerand,
2018). These biases, not unique to pain treatment, can result in unrelieved pain and
unnecessary physical, mental and emotional suffering for those in the minority
communities.
Despite the significant role that SES plays in the opioid epidemic, studying it is
challenged because most data resources do not contain direct measures of this factor.
Two of the more popular studies on relationship between SES and opioid prescription
rate were forced to use nSES (neighborhood socioeconomics) instead of SES. nSES is
determined based on the measures of average income, education and poverty level for the

64
patient’s zip code of origin (Gebauer, Salas, & Scherrer, 2017). The national study, using
NHAMCS data from 2006 to 2012, conducted a logistic regression and determined that
patient’s in the highest nSES bracket had greater odds of being prescribed opioids, even
with the same level of pain (Joynt et al., 2013). The results also indicated that Blacks and
Hispanics were less likely to be prescribed opioids, regardless of the SES bracket (Joynt
et al., 2013). A more recent study, using Primary Care Patient Data, contradicted the
previous study, as lower nSES correlated with greater odds of being prescribed opioids
(Gebauer et al., 2017). The researchers noted however, that this study restricted the
patients with to those with a ‘new’ diagnosis of back pain and that the findings indicate
the providers were non-compliant with the treatment guidelines for the new back pain
condition (Gebauer et al., 2017).
Prescription rate variation among ED providers. The research and anecdotal
evidence point to a connection between the increase in the rates of prescription opioids
and the increase in opioid-related injuries and deaths. The previous two decades has seen
a significant increase in the number of deaths from drug poisoning, and more specifically
rate for deaths by opiates have quadrupled (Pomerleau et al., 2016). These deaths are not
occurring in a vacuum as there is a concurrent increase in prescription rates across the
country. In 2008 there were 205 million prescriptions for opioids, but in 2012 almost 259
million OA prescriptions were filled, and even more were written (Mcdonald, Carlson, &
Izrael, 2012)(Pomerleau et al., 2016); Pomerleau, 2016). Specific to the ED, in 2008,
20.8% of all patients visiting the ED were prescribed an opioid, but in 2010 it rose to
31%, and 144,600 visits for non-medical use of opioids in 2004, would grow to 305,900
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fours later (Center for Disease Control & Prevention, 2010). Opioid prescription,
including those in the ED, and opioid abuse and opioid-related deaths are to be
correlated.
For providers in the ED, as with others who are involved in pain management,
treating pain means balancing the comfort of the patients with the risk of overdose and
addiction. Since over 42% of the ED visits are related to pain symptom (Centers for
Disease Control and Prevention, 2012), deciding whether to prescribe opioid and at what
dosage of the prescription is common decision for ED providers. These decisions are
complicated by the need to prioritize patient satisfaction and admonitions to beware of
potential abusers. The current prescription guidelines, though intended to help, are not
based on evidence but on the consensus of experts and are therefore not reliable (AMCP
Partnership Forum, 2015). Unfortunately, ED provider has received inadequate training
in balancing these many, nor does the ED setting afforded them the time or resources to
administer (Committee on Advancing Pain Research, Care, 2011). These shortcomings
cause each provider to make their own individual choices and as a result disparate
prescribing decision produce wide variation in prescribing patterns.
The report of the variation in ED prescription rates among providers was not
novel. Over a decade ago (Tamayo-Sarver, Dawson, Cydulka, Wigton, & Baker, 2004)
published finding that reflected the rising trend in opioid prescribing among ED
physicians. They reported that for patients requesting something strong for their pain,
10% of the physicians responded positively, 10% responded negatively, while mostly the
physician’s decisions varied significantly when faced with identical clinical scenarios
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(Tamayo-Sarver et al., 2004). But it would be almost a decade before the topic would
receive attention when physician and epidemiologists, Dr. Mazer-Amirshahi, would
conduct two studies on the subject. The first one reported on general opioid prescribing in
the ED (Mazer-Amirshahi et al., 2014), and another two years later, on the opioid
prescribing habits of attending physicians (Mazer-Amirshahi et al., 2016), and both
studies would reflect a troubling upward trend but that the rise was not uniform among
the different types of providers in the ED.
Other researchers have explored the concept of ED provider opioid prescription
rate variation. A study conducted in 2014 in two tertiary care military hospitals looked at
the prescribing practices among the various types of ED providers. Variables included the
list of opioids, the diagnosis of chronic pain both based on the International Classification
of Disease (ICD-9) codes, the provider type, provider gender, number of pills for each
prescription, the type of opioid and opioid refills if any (Ganem et al., 2014). After
applying these selection criteria on data for the last three years, 1,322 (out of 28,165 total
visits) patients qualified with a diagnosis of chronic pain, (Ganem et al., 2014). Opioids
were prescribed to 443 (34%) of the chronic pain patients, by 103 opioid providers, 79%
of whom were physicians and 19% were physician assistants (Ganem et al., 2014). The
results indicated that the physicians were more likely to prescribe opioids than the
physician assistants (Pas) (77% versus 45%) and the civilian doctors were also more
likely to prescribe opioids than the military doctors (58% vs 42%) (Ganem et al., 2014).
These results indicate that military doctors and PAs were more selective in their opioid
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prescribing, and this may reflect differences in training for each group relative to the
others.
So now that the variation rates were confirmed among the ED providers, what
factors cause these variations? A 2016 pilot study aimed at identifying some of the
factors influencing providers’ prescribing decisions was conducted among 203 ED
providers (Pomerleau et al., 2016). Though limited to one hospital, the study was a first
of its kind, with a variety of different types of providers. The participants included
attending physicians, residents, nurse practitioners and physician assistants, and the data
collection survey was a self-rating of the factors influencing their opioid prescribing
decisions. The researchers discovered that a patient’s opioid prescription history and their
history of substance abuse or dependence were the factors that had the greatest influence
on the provider’s prescribing decision (Pomerleau et al., 2016). Factors such as patient’s
diagnosis and level of distress were secondary, indicating that ED providers were giving
strong consideration of the link between the opioid prescription and the ill effects of the
drug. But despite these considerations there was significant variation in prescription rates
among these providers.
The same 2016 pilot study indicated that differences in provider training was one
of main factors influencing prescribing decisions. The attending physicians were found to
be less concerned about patient satisfaction or the prescribing culture, while the residents
placed less importance on the patient’s pain intensity or history of opioid use (Pomerleau
et al., 2016). The advanced practice providers (physician assistant and nurse
practitioners) did place higher importance on the pain intensity, patient satisfaction as
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well as history of opioid use (Pomerleau et al., 2016). This was in keeping with the idea
that the advanced practice providers tend to spend more time with patients are therefore
make better patient evaluation and provide superior patient care instructions. The
physicians that were least experienced, i.e. the residents, were more likely to be give
credence to the requests of the patients and to be more careful to abide with the
prescribing culture at the present institution (Pomerleau et al., 2016). It is possible that
these decisions are unique to the hospital, but it points to the need for additional training
for physician regarding the opioid prescription and pain management in the ED setting
and more research in this area provider prescription decision making
One of the most prolific researchers on the subject of opioid prescription rate, Dr.
Hoppes has published several of findings. One such research was a retrospective,
descriptive analysis that looked at opioid analgesic prescription variation for patients
presenting to the ED over a seven-month period at an urban academic hospital. The
participants were restricted by s diagnosis of lower acute back pain (LABP) and an opioid
analgesic on discharge (Hoppe et al., 2017). There were 23 ED providers, with an
average of 25 LABP patients each, resulting in 943 patients in this homogenous cohort
(Hoppe et al., 2017). The study found an alarming 22-fold variation in prescribing
proportions, which turned out to be 6-fold (12% to 78%) after adjusting for certain
patient and clinical characteristics (Hoppe et al., 2017). This significant variation among
ED providers, all at the same hospital, for a homogenous cohort, point a serious situation.
Given that prescribing practices are linked to opioid abuse and the opioid epidemic, this
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imply that more needs to be done as far as refining the guidelines, improving adherence
to the guidelines and educating providers.
Opioid abuse following emergency department exposure. Given the variation
in rate among ED providers, what is risk of addition once having received an opioid
prescription from one of these providers? A descriptive analysis was conducted to answer
this question. The researcher assessed the effect of opioid-prescribing patterns among ED
providers and the risk of future abuse, for Medicare beneficiaries visiting the ED during
the period 2008 to 2011 (Barnett et al., 2017). This retrospective study looked at the risk
of long-term opioid use after receiving an opioid prescription in the ED. They evaluated
opioid use for a year after the patient’s ED visits for those who had no record of opioid
use during the six months prior to their visit. The study divided the ED physicians into
quartiles, based on their opioid prescribing rates at their respective hospitals, based on the
dosage of opioids they prescribe. According to the findings, while the diagnosis was
similar among the two groups, 215, 678 received opioid prescriptions from low-intensity
prescribers and 161,951 from the high-intensity prescribers but there was 3.3-fold (7.3%
to 21.1%) variation in prescribing habits between the low-intensity and the high-intensity
ED providers and a significantly greater risk of long-term use among patients in the highintensity group (Barnett et al., 2017).
Another study sought to assess the risk of recurrent opioid abuse following an
initiation of use from an ED prescription. This descriptive retrospective study in an urban
academic institution Colorado evaluated all the opioid naïve (no previous opioid
prescription in the last year) patients diagnosed with an acute pain condition who were
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subsequently discharged from the ED over a period of five months. From a total of 5,597
patients records in drug monitoring program database, and 4,801 were selected for
analysis and little more than half (2,499 or 52%) were opioid naïve of the 1,420 (57%)
did not receive an opioid prescription in the ED 146 (10%) had recurrent use (Hoppe et
al., 2014). Of 1,079 who received an opioid prescription, 305 did not fill the prescription
and there was an 8% (23) recurrent use for them, and of the 775 who filled their
prescription had a 17% recurrent use (Hoppe et al., 2014). These results indicate that
receiving and filling an ED opioid prescription, for opioid naïve patients almost doubles
the risk of recurrent use in the future.
Yet another study attempted to describe the risk of opioid abuse and iatrogenic
addiction after initially exposure to opioids in the ED setting. A cross-sectional survey
study conducted on the ED patients presenting with heroin overdose or non-medical
opioid abuse symptoms at an urban academic teaching hospital. Of the 122 patients
approached, 59 subjects volunteered and completed the survey, and 35 (59%) of which
were revealed to have received their first opioid prescription legitimally, 10 (29%) of the
35 obtained them from the ED (Butler et al., 2016). Results indicated that it took six
months from exposure to the onset of non-medical use of opioid for 31 of the 35 (88.6%),
with 11 doing so in 2 (31.4%), 9 of whom had a history of substance or alcohol abuse
prior to their opioid exposure (Butler et al., 2016). The researchers concluded that
prescribing short-term opioid does not necessarily result in addiction, but it does play a
role in eventual abuse for a significant number of patients and more research, with a
greater number of patients, is needed to address this issue.
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In a most recent study that looked at the possible link between ED opioid
prescription and the potential for long-term use in opioid-naïve patients. Unlike the
studies discussed previously, this one compared the risk of ED prescription with risk of a
prescriptions received in settings other than the ED. The researchers used the data from
the administrative claims made by Medicare Advantage (elderly and disabled)
subscribers compared it with other commercial insurance and the analyzed the rate of
developed long term use, agreement with CDC guidelines, and the time from initial
prescription to long-term opioid use for both groups (Jeffery et al., 2018). The claims
data for the period 2009 to 2015, found that of the 5.2 million opioid prescription filled,
that 13.4% (twice as likely) of disabled beneficiaries were more likely to progress to
long-term use compared with the 6.2% of the elderly, and only 1.8% for the
commercially insured (Jeffery et al., 2018). Interestingly, the ED prescriptions were more
compliant with the CDC guidelines than non-ED prescriptions with respect to lower
dosage, immediate-release formulation and shorter number of days (Jeffery et al., 2018).
Additionally, the commercially insured (46%) were least likely to progress to long-term
use, compare with the aged (56%) and the disabled (58%) Medicare beneficiaries (Jeffery
et al., 2018). The authors noted caution about the ED apparent compliance and the
correlation with lower risk as this study was the limited by several factors including:
short time measure for determining long-term use; only 2% of the dosage was for longacting, extend release form; and a previous history of substance abuse was not considered
(Jeffery et al., 2018).
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The outcome of opioid prescription guidelines. Prescription medications are the
primary cause of injury death, with most of the drugs involved being opioid analgesics,
and the lack of any increase in pain complaints is contrasted with a significant increase in
opioid prescriptions dispensed in the ED (Mazer-Amirshahi et al., 2016). The persistence
of this trend and the established link between long-term opioid therapy and physiological
dependence and addiction made addressing this issue a priority. The ACEP chapters of
Washington and Oregon states (and eventually New York) were the first to create
prescribing guidelines that essentially advised against prescribing long-acting opioids,
limiting prescriptions to a three-day supply, and desisting from replacing lost
prescriptions (Poon, 2014). But the example set by these three states were not readily
embraced by other states, who either chose no prescribing guidelines or use some other
strategy.
Other EDs tried to address the problem by implementing prescription drug
monitoring programs (PDMPs), an internet based database for recording and looking up
patient’s prescription drug history, established in 2008 (Hoppe et al., 2015). But the few
studies conducted to investigate the effect of PDMPs on provider prescribing behavior
have shown not so positive results. One state wide study in Ohio found that use of
PDMPs resulted in a 40% change in prescribing behavior, and 66% the providers who
changed decreasing their rate, while 40% increased theirs (Baehren et al., 2010). A
smaller study of 38 ED providers found that the change in prescribing behavior following
PDMP implementation was minimal (9.5%) most of which was an increase in opioid
prescriptions (Weiner et al., 2013). Yet another study among attending and resident
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physicians found an overall decrease in prescription, but incidentally, 38% of the
attending increased their prescription after exposure to the PDMPs, while not resident did
(Feldman, Skeel Williams, Knox, & Coates, 2012). A national survey medical
toxicologist revealed that most had either not heard of the PDMPs and those who did
found them too difficult to access and use (Perrone, DeRoos, & Nelson, 2012). These
state-wide PDMP may have potential to help ED providers reduce the risk of opioid
abuse in some patients, the tool needs more work and it adoption and use needs to me
universal before the real benefits are experienced.
The concern for the opioid-related deaths have resulted in the several agencies
instituting their own guidelines governing the prescription of opioids. On a national level,
the FDA amended their risk evaluation and mitigation strategy (REMS) program for
including in the physician education curriculum information concerning the
administration of long-acting and extended-release opioids (Sheldon, 2011). On the state
level Utah, Washington, and New York, developed their own respective opioid
prescribing guidelines to specifically address the EDs to reduce the inappropriate use
while still meeting the need of patients for effective analgesia (Neven, Sabel, Howell, &
Carlisle, 2012). The Washington state Medicaid also instituted a policy that would deny
payment for unnecessary visits ED, forcing ED providers to adopt “best practices”
guidelines (Neven et al., 2012). The American College of Emergency Physicians (ACEP)
and the CDC have provided clinical policy related to prescribing opioids in the ED. The
Oregon chapter of the ACEP published guidelines advising for consistency and against
replacement prescriptions opioids in the ED, (Notenboom, 2017).
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Clinical policies produced by the ACEP together with the FDA and the CDC
sought to address several issues related to the administration of opioid to patients in the
ED for who opioid would be the “appropriate treatment modality” (Cantrill et al., 2012).
As studies have demonstrated, that although the PDMP was designed for improvement
but due to the many limitations, garnered only partial success. The absence of high quality research concerning the effectiveness of opioids long-term and or relative to other
treatment options leads physicians to rely on their own judgement and experience. ED
patients invariably include opioid abusers, yet no randomized controlled trial (RCT) or
prospective observational cohorts are conducted to understand this demographic. Also,
comparison the effectiveness and eventually standardization of the metrics used in the
different PDMP across the different states is critical. Studies examining the use the
different opioid types (hydrocodone, oxycodone and fentanyl) compared with non-opioid
therapies and the historical factors of the ED patients. Finally, understanding the postdischarge behavior of opioid prescribed patients relative to the follow-up provisions
stratified by pain complaint, diagnosis as it relates to results and opioid diversion.
The NYC ED discharge guidelines for opioid prescribing consisted of a set of
nine directives or advice modules (Chu, 2013). The note states that the guidelines should
not replace clinical judgement and they should not replace appropriate patient care as
determined by the physician. In summary, providers are admonished to consider shortacting opioid, starting with the lowest dose and short course. The patient should be
assessed for current opioid use and abuse history, use non-opioid analgesics for recurrent
pain. According to these guidelines, the long-acting drugs are sustained-release
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oxycodone, methadone, sustained-release morphine, fentanyl, and the extend-release
form of oxymorphone, and hydromorphone. The short-acting drugs are codeine,
immediate-release oxycodone, Vicodin, immediate-release morphine, hydromorphone,
and immediate-release oxymorphone.
Despite treatment guidelines, which are no more than suggestions since they lack
backing of any research evidence of benefit or long-term outcomes, there are significant
variations in prescription pattern (National Academies of Sciences, Engineering, and
Medicine, 2017). In fact, the limited evidence that exists points to significant harm and
addictions, which is supported by the present opioid epidemic. In many cases, the
descriptive studies indicate that despite efforts at intervention, treatment guidelines and
use of prescription drug monitoring programs (PDMP), there is very little consensus even
when the patients present with identical scenarios (Hoppe, 2017). These ED providers are
on the frontline in dealing with the issue of pain management in the field and doing their
best to provide quality healthcare. This has motivated ongoing research to understand this
variation among ED providers in the hopes of minimizing it.
Summary and Conclusions
Pain is a universal experience and the oldest medical problem, and the history of
medicine and public health is rich with tales of the efforts to respond to and deal with this
condition. Treating pain has evolved over the centuries from incantations, gases and
potions to pills and injections, and technological advancement made pain treatment more
and more effective. One of the themes that runs through the story of pain management is
the use of the opium in various form as well as the accompanying problem of abuse and
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addiction. But opioids, in its many forms remains one of the most powerful options for
dealing with chronic, severe pain and this is evidence by its widespread use in the
practice of medicine. The widespread use of opioids, both legally and illegally, has
resulted in the opioid epidemic, which is now a major public health crisis.
As the most common condition for which patients turn to medical treatment in the
ED, ED physicians in the ED are at the frontline of the struggle to pain management
administration. They are faced with the challenge of relieving patients’ pain while at the
same time mitigating their risk of opioid misuse, abuse and addiction. While much of the
focus of the response to the opioid epidemic have been on patient’s characteristics,
evidence exists that provider biases also play a role. The prescribing decisions of ED
providers are consciously and unconsciously affected by their perceptions of their
patients as well as their own traits and experiences. Limited research has indicated
differences in prescribing behavior among ED providers that results in pattern variation,
but more needs to be understood about this. Despite the prescribing guidelines and the
prescribing monitoring programs, these patterns persist, indicating the need to more
research into the drivers behind these prescribing patterns so that they can guide the
development of effective intervention strategies.
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Chapter 3: Research Method
Introduction
The objective of this research was to determine the role of ED provider type on
the rate of opioid prescription occurring in the ED. In this chapter, I describe the subjects
and the methodology employed to address the research questions. The analysis was
performed on secondary data (the NHAMCS), which were collected by the NHCS. The
surveys conducted by the NHCS are designed to provide health care statistics to those
who conduct research on various topics involving health care organizations and the
services they provide to the U.S. population. The NHAMCS contains information on
opioid prescriptions by ED providers to patients visiting the ED, which made it ideal for
answering the research questions.
The chapter is divided into three main sections culminating in an overview of the
data analysis procedure. The first section includes the characteristics of the sample
participants or subjects, information on how they were selected, and a description of how
missing data or attrition was treated. The second section includes information on the
instruments used to collect the data, the data collection procedure, and the various
measures and constructs that are included in the data set. This section also includes a
discussion of the external and internal validity associated with the research methodology.
In the final section of the chapter, I present a detailed description of the data analysis
plan, complete with a discussion of each of the research questions, the related statistical
tests, the rationale for choosing the test, and the means by which results were evaluated
for statistical significance.
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Research Participants
The NHAMCS of the NHCS
The National Hospital Ambulatory Care Survey (NHAMCS) and the National
Ambulatory Medical Care Survey (NAMCS) are the two survey instruments devised by
the National Center for Health Statistics (NCHS), a branch of the Centers for Disease
Control and Prevention (CDC), used to collect information about health care utilization
across the various medical institutions around the United States. The ambulatory medical
care provided in physicians’ offices all over the United States is the principal means by
which the majority of Americans access health care (Hsiao, 2010). Beginning in 1973,
the NAMCS was used to collect and publish relevant information on these visits (Hsiao,
2010). Almost 20 years later (1991), NCHS created the NHAMCS to broaden the scope
of the collected data to include community health centers, hospital EDs, outpatient
departments, and all types of ambulatory surgery locations (NCHS, 2015a). The objective
was to gather information about the health care provided by hospital emergency and
outpatient departments across the United States and to make it available to the public
(NCHS, 2015a).
Adding the NHAMCS to the NHCS activity was important because visits to
hospital emergency and outpatient departments (OPD) make up the second largest (after
ambulatory care provided through physician’s offices) segment of medical care in the
United States and comprise a different patient demographic (CDC/NCHS, 2017). At the
start, there were 1.43 billion ambulatory visits, 164 million of which were to EDs and
OPDs, annually (McCaig & McLemore, 1994). Collecting the relevant data became
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increasingly necessary as the population aged rapidly and there was an increasing number
of patients without health insurance, along with a growing array of medical modalities.
There was a growing sense that it was important to understand the impact of these
societal changes on the organizations involved and on the delivery and cost of
ambulatory care in the United States. In response, the NHCS convened a panel of experts
from the National Academy of Sciences and the Institute of Medicine and outlined the
design for a survey that would reach out to those involved in hospital ambulatory medical
care (McCaig & McLemore, 1994). Together with the NAMCS, the NHAMCS has
become an invaluable tracking instrument, collecting important health care utilization
data from across the country and making it publicly available to those who wish to use it.
Both the NAMCS and the NHAMCS survey instruments have been revised and
updated several times since they were first introduced. Additional questions were added
to both in 2003 to reflect changes to electronic health record systems, while in 2006, a
new stratum of community health centers was added to the NAMCS (CDC/NCHS, 2017).
Another change was the assignment of unique drug codes for all pharmaceuticals based
on the Multum’s Lexicon Drug Database, where each drug containing multiple
ingredients was given a single code to replace the generic drug code for each ingredient
(CDC/NCHS, 2017). Additionally, in 2010, makers of both surveys began collecting
laboratory tests results, and a year later the five-fold increase in sample size for the
NAMCS allowed for state-based estimates of health care utilization (NCHS, 2015b).
Finally, beginning in 2012, the clinical data on cardiovascular diseases and stroke were
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monitored by a heart disease module that was added to both survey instruments (NCHS,
2015b).
Sample Selection for the NHAMCS
The intent of the NHAMCS was to gather information about the ambulatory care
provided in hospital emergency and outpatient departments, and it includes both freestanding and hospital-based institutions (NCHS, 2015b). Although both OPD and ED
data are collected, the public files contain only data from the ED surveys. Ambulatory
care is the way most Americans receive medical care, and the NHCS, recognizing that
differences in demographics and other characteristics might affect ambulatory care visits,
instituted the NHAMCS to gain a more complete picture of the national patient profile.
The data file published by the NHAMCS contains an account of each patient visit,
including the medical record pertaining to each visit, the characteristics of the ED
personnel providing the care, and the facility for each institution in which the ED is
located (NCHS, 2015b). Not all the variables collected in the survey are included in the
published form, but they can be formally requested from the NHCS.
The NHAMCS is designed to be a national representation of patient visits made to
hospital EDs, outpatient surgeries, and outpatient clinics, excluding federal, military, and
Veteran Administration hospitals, in all 50 states and the District of Columbia (CDC,
2017). The sampling was based on geographic location, specifically counties, and the
various emergency service clinics in the hospitals found in each location. Data for the
NHAMCS are collected from the patients’ medical records and include notes on their
demographics (age, gender, race / ethnicity), their symptoms and reason for visit, the
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diagnostic and screening services provided, the types of health professional seen, the
diagnosis received, and the medications prescribed (Hsiao, 2010; McCaig & McLemore,
1994). One of the advantages of the NHAMCS over similar research data collected is the
inclusion of institutions other than academic medical centers (Kea, Fu, Lowe, & Sun,
2016a). Inclusion of these data helps the NHAMCS provide a more well-rounded view of
health care services and the patient body receiving care in the ED and OPD. This also
makes the findings based on its analysis more generalizable.
Sampling Process for the NHAMCS
The NHAMCS was designed to collect a probability sample of visits to the ED to
generate a national estimate, using a four-stage sampling design (National Center for
Health Statistics, 2015b). The process starts with sampling across the entire U.S., then
from specific regions in the U.S., followed by the emergency departments located in
those regions, and finally from the various types of institution-ownership for each of the
EDs. The outlined sample selection included the following four steps:
1. Sampling counties or metropolitan area from the 50 states and D.C., selecting
112 primary sampling units (PSUs) from among 1,900.
2. Selecting from each of the PSUs, hospitals meeting certain eligibility
characteristics and also providing ED services
3. Choosing different ownership types from the eligible hospital with ED,
excluding all Federal and institutionalized hospitals and assigning those with
less than six in-patient beds to a separate stratum.
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4. Finally, selecting a designated number of patient records, from all ED visits,
for eventual inclusion in the data set.
The first-stage of the sampling process was based on geographic location and
generated 112 PSUs. This came from a subsample the total of 1990 PSUs, based on
counties, groups of counties, county equivalents, towns, townships, minor civil divisions,
or metropolitan statistical areas (National Center for Health Statistics, 2015b). The
original numbers were according to the 1980 Census of Population (1985-1994 NHIS)
projection, and were stratified based on socioeconomics, demographics, and population
size (National Center for Health Statistics, 2015b). Those selected for the NHAMCS
included 26 of the largest PSUs, 26 of the second largest PSUs and then one from each of
the remaining strata of the PSU population (National Center for Health Statistics, 2015b).
Selecting hospitals from the 112 PSU involved finding ones that were in the 1991
SMG Hospital Market Database and had an average stay of less than 30 days per patient,
as well as a general (medical or surgical) or children specialty and not deemed Federal,
institutional or military hospital (National Center for Health Statistics, 2015b). Of the
6,249 eligible hospitals, 5,582 (89%) had EDs and 5,654 (90%) had OPDs, and were
classified into four categories (ED only, OPD only, ED and OPD, and no ED or OPD)
(National Center for Health Statistics, 2015b). Further stratification was based on hospital
size, on volume of visits, type of ownership (non-profit, for-profit), and region (National
Center for Health Statistics, 2015b). Included EDs were selected from each of the
necessary stratum and assigned for data collection.
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Of the various PSU categories, systematic random sampling yielded 550
hospitals, with an ED and/or OPD, which were divided in groups of 30-35, with every
group assigned to a 4-week reporting period (National Center for Health Statistics,
2015b). Based on the selection criteria, 377 of the 457 hospitals qualified as having 24hour emergency services, but only 267 agreed to participate in the survey, resulting in a
70.8% sampling response (National Center for Health Statistics, 2015b). Of the 267
participating hospitals, 83% complied with the minimum requirement of providing the
forms for at least half of their expected sample visits, yielding a total of 21,061
completed electronic Patient Record (PRF) forms, resulting in an initial response rate of
77.8%, and an overall sample response rate was 55.1% (77.8 x 70.8%) (National Center
for Health Statistics, 2015b).
Method of Data Collection
Field Representatives and Confidentiality
The data collection was conducted by staff from the U. S. Census Bureau, which
selected and trained the Field Representatives (FRs) and monitored the data collection
process. There was a 6-week obligatory induction phase, prior to the 4-week reporting
period, during which the ED staff were trained with the permission of the hospital
administration (National Center for Health Statistics, 2015a). During induction, the
assigned FRs worked with the ED department staff to verify eligibility, and to obtain
necessary IRB approval. This induction also involved sending out correspondence,
contacting the administrators, collect relevant data about the institution, and developing
appropriate sampling plans. Once inducted, the ED staff was trained in the correct data
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collection procedure and the proper use of the Patient Record forms (PRFs). Since the
2015 NHAMCS data is based on computer-assisted tool, that replaced the paper-based
ED record forms in 2012, all of all ED records are now completed by the FRs (National
Center for Health Statistics, 2015b). The hospital staff collected daily listings of all visits
during the assigned 4-week reporting period and the FRs selected the visits, based on the
predetermined systematic random sampling, to generate at least 100 PRFs per ED clinic.
Under the guidance of the Research and Ethics Review board of the NCHS and
the Health Insurance Portability and Accountability Act (HIPPAA) the data collection
was safeguarded. No personally identifying information (name, address, Social Security
number, etc.) was collected by the NHAMCS and in 2013 informed consent and patient
authorization requirement waivers were granted allowing the release of medical record by
relevant healthcare provider (National Center for Health Statistics, 2015b). The FRs, who
were trained in the Privacy Rule on how hospitals can disclose limited health information
for research without violating in privacy laws, masked identifying confidential
information on the patient or the facilities for values like ‘race’ and ‘diagnosis’, and top
coding values such as ‘age’ (National Center for Health Statistics, 2015a). The NHAMCS
data is publicly available, but approval from Walden’s Institutional Review Board was
obtained prior to conducting research on the data.
Instruments: Survey Material
The automated survey tool (see Appendix A) used for the 2015 NHAMCS data
collection, first distributed in 2012, was redesign from the traditional paper-based version
to make computer-assisted data collection possible (Center for Disease Control and
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Prevention, 2017). The redesign included additional specifications about the survey’s
appearance, -changes in wording, answer choices, and variable length- as well as the
addition of a number of new help-screens and prompt-fields to improve data entry
accuracy (National Center for Health Statistics, 2015b). The initial visit of the field
representative was for the induction into the use of the hospital induction form (see
Appendix B). This determined the list of all ED clinics and service areas at each hospital,
and further classification based on expected number of patient visits over a the 4-week
period (National Center for Health Statistics, 2015b). Selecting the records to include in
the data set required satisfying specific criteria, as visits were to be defined as a direct,
personal exchange between patient and provider (physician, staff member acting under
physician’s direction), for seeking care and rendering health services. The number of
Patient Record forms collected were obtained with a random selection of every nth visit,
based on the expected number of patients and the desired number of 100 for each ED
(National Center for Health Statistics, 2015b).
Validity and Variance Estimation
The sampling variability is measured by the relative standard error (RSE), which
is expressed as a percentage and is calculated by dividing the standard error of the
estimate by the estimate itself. The SUDAAN software was used to produce the standard
error as it accommodated the complexity of the sample design, especially for clustered
variables such as ‘race’ and ‘source of payment’ (Hsiao, 2010). Software packages such
as SPSS is useable with the 2015 estimates, if not combined with previous years. It may
produce underestimation and a higher likelihood of Type 1 error, and a significant
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difference at an alpha of 0.01 level (instead of 0.05) was recommended by the NHCS
researchers (National Center for Health Statistics, 2017).
The data processing involved several steps for checking, configuring and
transforming the data into the files that are published and the NCHS FRs were charged
with reviewing to check for errors. The quality control for the medical and drug coding
operations was subject to a two-way, independent verification process and after
independently re-keying and recoding a random selection of 10% of all PRFs, the error
rate was between 0.3- 0.9% (National Center for Health Statistics, 2015a). All coding
variations or illegible entries for cause of injury, medication items, diagnosis, etc. were
reviewed and resolved by the NHCS team. According the NCHS the relatability of
certain estimates must be based on records that are more than 30 and have a relative
standard error of 30% or less, values of which are provided in the appendix for the data
summary file. These estimates are produced from the ‘patient visit weight’, as the file
contains an entire sample of 21,061 visits representing an estimated 136,943 visits made
across the U. S. (National Center for Health Statistics, 2017).
Research Design and Approach
Secondary Data: NHAMCS Data Set
All the data collection and processing for the NHAMCS was conducted by the
U.S. Census Bureau field representatives (FRs). These FRs worked with the hospital staff
ensure that the data collected was accurate and reliable. The patient information included
demographics, reason for visit, vital signs, cause of injury, diagnostic test, diagnosis,
procedure received, medication prescribed, provider consulted, and disposition. This
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current research will use only the 2015 NHAMCS data and will include the specific
variables- ‘opioid prescription’ as the dependent variable; and ‘provider type’ as the
independent variable, and ‘race’ and ‘payment source’ as possible interaction variables,
and measures of ‘age’, ‘gender’, ‘pain-scale’, and ‘triage’ as control variables. The
reported measures are based on sample data that was weighted to produce unbiased
annual national estimates and include standard errors for each estimate. The visit weights
take the survey design into consideration and are based on four elements: inflation by
reciprocals, adjustment for nonresponse, population ratio adjustments and weight
smoothing (Kea et al., 2016a; National Center for Health Statistics, 2015a). The results
are subject to both sampling and non-sampling errors, from reporting and processing
errors as well as from incomplete or missing responses.
Sample Size Determination
Determining the appropriate size of the sample is required to ensure reliability of
detecting the true effect, if it exists, and adequately answering the research questions.
Generally, sample size determination involves several simplifying assumptions and the
greater the variability in the outcome variable the larger the sample size required
(Substance Abuse and Mental Health Services Administration, 2016). For this research
the question of determining the effect of ED provider type differences on the probability
of opioid prescription, logistic regression analyses conducted. For this type of analysis,
there are some basic parameters that should be considered: i) how precise should be the
estimations; ii) how reliable are the results; iii) how much variation is acceptable; and iv)
how small of an effect size is expected (Substance Abuse and Mental Health Services
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Administration, 2016). Fortunately, there are many tools available that allow the use of
educated guesses, guided by previous research, to make reliable a priori determination of
sample size for this type of statistical analysis.
The G*power analysis tool was used to determine the sample size for this
quantitative, statistical analysis. Although there are no specific guidelines available for
using this tool for logistic regression, some extrapolation based on its use for other tests
have proven useful. Research conducted on the subject of variance in the rates of opioid
prescription reported ranges as low as 11% and as high as 40% (Rogers, 2018; Sasson et
al., 2018), and odds ratio between 0.5 and 1.3 (Barnett et al., 2017; Pletcher et al., 2008),
depending on diagnosis, patient characteristics, hospital type, provider type, etc. (R. M.
Dickason et al., 2015; Hoppe et al., 2017; Jeffery et al., 2018; Ringwalt, Roberts,
Gugelmann, Cockrell Skinner, & Author, 2015; Weiner et al., 2013). This information
was used to make predictions about the variability measures and effect size among ED
providers in this data set, and these predicted values were then entered into the G*power
software for sample size determination. The specific selections included: Test family “z”;
the Statistical test “Logistic Regression: Fixed effects, omnibus, one-way”; as well as the
Type of power analysis “A priori: Compute required sample size- given α, power, and
effect size” (Faul, Erdfelder, Lang Albert-Georg, & Buchner, 2007). The following
constraints were used to compute the recommended sample size: odds ratio (representing
the effect size) = 1.2; X distribution = binomial (for logistic regression), the power =
0.95; and an α = 0.01 (for confidence level).
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Figure 6 G*Power Sample Size Estimation Output
Power analyses for sample size estimations usually assumes several standard
conditions. For linear regressions, these assumptions include normality of the outcome
measures, that the error variances among the dependent variables are the same, and that
the projected magnitude of the effect size to be detected is correct. For logistic regression,
these assumptions are not valid as it is a non-linear model, however a conservative
estimation can be determined using reasonable guidelines as have been done in this
present study. Using an effect size of 1.2 (odds ratio), which is considered very small for
this type of analysis (Ellis & Paul D, 2010), and the NHAMCS recommendation of an
alpha of 0.01 (to reduce the chance of a Type 1 error) generates a sample size that is more
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than adequate for the detection of differences among the groups being investigated
(National Center for Health Statistics, 2015a). The values used generated a sample size of
16,073 and since the data contain more than 21,000 records (representing over 300,000
adjusted visits), it more than meets the necessary power requirement.
Outcome or Dependent Variable: Rate of Opioids
For this study, the outcome variable is the dichotomous response to the question
of opioid prescriptions by administered by the ED providers and this new variable was
created from the list of prescriptions recorded for each visit. The drug characteristics,
assigned using the Multum’s Lexicon Drug Database, were coded based on generic as
well as their therapeutic components and analgesic prescriptions. The Multum, which is
part of the Lexicon Plus database, is a comprehensive database of all prescriptions and
some non-prescription drugs on the U.S. market (Cerner Multum, 2018). Analgesics were
the most commonly prescribed pharmaceuticals in the ED, amounting to 95,490 (28% of
the 340,551) of the reported drug mentions given in the ED or prescribed at discharge
(National Center for Health Statistics, 2017). Each drug or each drug-combination is
assigned its own unique code, and any mention of an opioid containing ‘central nervous
system’ pharmaceutical was considered an opioid or opioid pain reliever (OPR)
prescription. The new variable distinguished OPRs from all other pharmaceuticals, where
‘0’ will represent no OPR prescribed and ‘1’ represented at least one OPR.
Independent Variable: ED Provider Type
The main predictor variable is the ‘provider type’ of each of the ED provider and
reflect their level of training or their medical background. For the purpose of this study,
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medical professionals fall into two main categories, those that authorized to write
prescriptions and those that are not. In the ED, prescriptions can be written by five
categories of ED providers- the attending physician; the resident or intern physician; the
consulting physician; the nurse practitioner; and the physician assistant. The various
provider types who are included in the main dependent variables are defined in the
documentation file as follows:
1. Attending physician: the physician primarily responsible for the patient’s care
while in the ED and may also be responsible for supervising training interns,
residents and medical students.
2. Resident or Intern (first-year) physician: the physician is a recent graduate of
medical school and is receiving training in emergency medicine practice.
3. Consulting physician: is the physician called to the ED by a provider to
provide consulting care in his or her area or expertise.
4. Nurse Practitioner: an advanced practice registered nurse with qualified
clinical competencies beyond that of an RN.
5. Physician assistant: a medical professional who is certified to practice
medicine in under the supervision of a physician.
These variables were provided as dichotomous variables each, in the data set and were
used as the main independent variables in the logistic regression analysis.
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Covariate #1: Race/Ethnicity
The first covariate was that of the race/ethnicity measure for the ED client in each
visit. Unlike other aspects of the survey data, with the ‘race’ value record was completed
by hospital staff (and not the trained FRs), and despite adjustments, there was still
concerns for bias, as 19.4% records for ‘race’ and 24.2% for ‘ethnicity’ were reported as
missing or non-response (National Center for Health Statistics, 2017). Fortunately, the
weighting of the data that was started in 2005 enables the calculation of department-level
estimates. These estimates assume that non-responding facilities had the same
characteristics as those responding and therefore the weighted estimates correctly reflect
the sample estimates at both the department level and the means of visit characteristics
for each variable. This ensures that the variables such as those for race and ethnicity are
reliably represented in the data set.
The population estimates in the 2015 NHAMCS ED survey for the different racial
groups were based on the 2010 U.S. Census data. The ethnicity variable was used to
describe the patient’s national or cultural group with which they identified. In the
published data set there is a Race/Ethnicity variable and it contains four categories: NonHispanic White, Non-Hispanic Black, Hispanic and Non-Hispanic Other (National
Center for Health Statistics, 2017). However, starting in 2009 the NHAMCS resorted to
including only three main categories for ‘race’ to eliminate the low-quality race data
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(related to other minority races): White and Black, and Other. It is this variable with the
three categories what used in the data analysis.
Covariate #2: Source of Payment
The second covariable assessed was that of ‘source of payment’ or how each
patient paid for ED service provided, and it is also categorical. This variable was used in
place of data pertaining the socioeconomic status, as there was no direct measure of this
value. The variable PAYTYPER as recorded in the data set, represents the primary
source of payment and was based on the hierarchy of payment options (National Center
for Health Statistics, 2015b). The eight options available for responding to the question
include:
1) Private insurance: paid fully by private insurer (Blue Cross/Blue Shield) or
partly (deduction or copay plan) and excluded Medicare Advantage
2) Medicare: paid fully by Medicare or in-part (copay, deductible, reimbursement,
etc.) and included Medicare sponsored prepaid plan, Medicare Advantage (including
Health Maintenance Organizations (HMOs), Preferred Provider Organizations (PPOs),
Medicare Medical Savings Account Plans, etc.
3) Medicaid or CHIP or other state-based programs: paid in full or in-part by
Medicaid plan either directly to the hospital or reimbursed to the patient.
4) Workers’ Compensation: charges paid by programs that provide for employees
injured on the job qualified to receive financial compensation
5) Self-Pay: charges (excluding copays or deductibles) to be paid by patient or
patient’s family and will not be reimbursed by third party
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6) No Charge/Charity: no fee is charged and includes services provided as charity,
special research or teaching purposes.
7) Other: source of payment not covered in any of the above categories and may
include organizations such as TRICARE, state and local governments, private charitable
organizations and other liability insurance (automobile policy coverage).
8) Unknown: used if the source of payment is unknown or undetermined.
For this research, this variable was regarded as an ordinal variable, with a pseudo
ranking based on the hierarchal nature of the categories (as assigned by NHCS). This
hierarchal covariate was added as a covariate to the logistic regression analysis and used
determine the effect of ‘payment source’ on provider type on opioid prescription rate.
NHAMCS Summary Data File Supplied by the NHCS
In the NHAMCS data file, the sampling unit is represented by each patient visit to
the ED and a record of patient’s visit was defined as a direct, personal exchange between
a patient and an ED provider. Only interaction between patients who sought care and
received health services were considered official, while visits intended for making
payment or dropping of samples, where no medical care was provided, were not. The
published summary of the data is based on analysis of the sample visit weight produced
from the corresponding sampling fraction at each the sample design stage with respect to
time of year, geographic region, hospital ownership (National Center for Health
Statistics, 2017). These unbiased estimates provide values of the predictor variables for
each of ED visit occurrences, along with percentages, and other important characteristics
for comparison and analysis. For each ED visit, a list of all the drugs prescribed are
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provided by name and type and is recorded along with several other factors, including
patient’s race and gender, as well as the associated date, condition, diagnosis, payment
type, vitals, discharge or admitted, etc. This study used several of those variables as
predictor variables and covariates, based on their relevance to ED prescription variability.
Statistical Research Design
Research Approach: Logistic Regression
Logistic regression is used to analyze data sets containing several predictor
variables and a dichotomous outcome. It is a common statistical analysis in medical
research because it is able determine strength of association and to predict risk of disease
(or even death) while controlling for several confounding effects (Stoltzfus, 2011).
Logistic regression analysis is suitable for longitudinal data, which is collected on the
various predictors believed to be associated with an event and these independent or
predictor variables can be either categorical, or continuous (Stoltzfus, 2011). In this
study, the outcome was the presence or absence of an opioid prescription, the predictor
variables include was the ED provider type, and the confounding variables were the race
of patient and the type of payment used.
Like linear regression analysis, logistic regression is used to build prediction
models, except with the latter, the model is based on probability or likelihood. Logistic
regression analysis generates a model with a regression coefficient for the each of the
predictor variables, the exponential of which represents the odds ratio or the change in
the odds of the event relative to a change in the predictor value (Sperandei, 2014). In
logistic regression, the categorical nature of the outcome violates the regular assumption
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of linearity, but it is assumed that there is a linear relationship between the predictor
variables and the logit of the outcome variable and so that the strength of the relationship
can be correctly estimated (Field, 2014). The other assumptions of logistic regression
included the independence of observations, independence of errors (homoscedasticity),
absence of multicollinearity, and a sample size large enough such that the least frequent
outcome has a minimum of 30 cases for each independent variable (Joglekar, 2015; Lani,
2015; Stoltzfus, 2011).
Assessment the contribution of each predictor was based on the value of its
exponential of regression coefficient, the odds ratio, and the respective statistical
significance (Field, 2013). A regression coefficient other than zero indicates an effect on
the outcome, but a p-value less than α (in this case 0.01) tells whether the effect on
predicting the outcome is statistically significant. For determining the statistical
significance of the odds ratio, the 95% confidence interval (CI) will also be used, as it
represents the range within which the odds ratio value found, 95% of the times this
analysis, if conducted on the given data set (Sullivan, n.d.). The precision of the OR value
estimated from the position and size of the CI, as a smaller range reflects a more precise
measure, and a range that does not cross “1” indicates a genuine effect (Sullivan, n.d.).
Data Analysis
Research Question 1: Provider Type Variation
RQ 1: Is there a significant association between provider type and the rate of
opioid prescription in the ED?
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H01: There is no significant association between provider type and the rate of
opioid prescription in the ED?
Ha1: There is significant association between provider type and the rate of opioid
prescription in the ED?
A binary logistic regression analysis requires a dichotomous outcome variable,
therefore the ‘absence or presence’ of an opioid prescription was used to create the
dependent variable. Although this research involved the analysis of drug data, no separate
drug file was generated, avoiding corruption of the estimation of variance. This new
variable was generated from the list of drug names (from the Multum’s drug code
database), recorded for each ED visit, and it was used for all the subsequent analyses in
this study. For the first research question, the independent variable was the classifications
for the ED provider, already available as dichotomous variables in the data set, was used
in the multiple logistic regression (MLR) modelling along with the covariates AGE,
PAINSCALE, TRIAGE, and SEX. The odds ratio (OR) generated was used determine
the relative strength the influence of each of the variables on the opioid prescription
outcome. The statistical significance, and the rejection of the null hypothesis, was based
on the p-value of the z-statistic (Wald statistic) and the confidence interval (CI) of each of
the corresponding OR.
Research Question 2: Provider Type and Race
RQ 2: Is the association between provider type and the rate of opioid prescription
influenced by the race of the patient?
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H02: The association between provider type and the probability of opioid
prescription is not dependent by the race of the patient.
Ha2: The association between provider type and the probability of opioid
prescription is dependent by the race of the patient.
Addressing this research question required the inclusion of an additional
independent variable (moderator) and an interaction variable into the logistic regression
equation. The dependent and independent variables were the same (Opioid Prescriptions
and the Provider Types) as in the first research question, but the RACE variable (the
‘race’ of the patient to whom the medication is prescribed) was added. This analysis also
required the creation of an interaction variable (Provider Type x Race) and the generation
of two models. The multivariate logistic regression (MLR) was used to estimate the
interaction between the independent variables with respect to its effect on the dependent
variable. The first model consisted of the DV (Opioid Prescription) and two IVs, (the
Provider Type and Patient’s Race); and in the second model the DV was the same, but
the interaction variables was added (Provider Type x Race) for each of the Provider Type
that was significant in the first. The p-value and CI of each the variables (non-interaction
and interaction) was used to determine whether the statistical significance in the models.
Research Question 3: Provider Type and Payment Type
RQ 3: Is the association between prescriber type and the rate of opioid
prescription influenced by the patient’s “expected source of payment” variable?
H03: The association between prescriber type and the rate of opioid prescription is
not influenced by the patient’s “expected source of payment” variable.
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Ha3: The association between prescriber type and the rate of opioid prescription is
influenced by the patient’s “expected source of payment” variable.
Another MLF analysis was conducted to answer third research question. The DV
(opioid prescription) and the main IV (Provider Type) remained the same as in the second
research question, but the new moderator variable was ‘Payment Type’. Like research
question 2, two models were generated, with model #1 having the two IVs (Provider
Type, and Payment Type) and model #2 having three IVs (Provider Type, Payment Type,
and an interaction term, Provider Type x Payment Type). The various statistics used to
assess the influence of the new moderator and that of the interaction term on the
prediction of the outcome, probability of an OPR prescription. The p-value and the CI of
the regression coefficient for the MLR formula in model #2, was evaluated for rejecting
or accepting the null hypothesis.
Summary
The purpose of this research project was to examine the role of the provider type
on the rate of opioid prescription in the emergency department. The data set was obtained
from the National Hospital Ambulatory Care Survey (NHAMCS) data set, which collects
information about health care utilization from institutions around the country. The public
file of the NHAMCS represents patient visits made to ED and contains extensive
surveyed information about the patient and is collected and processed by the NCHS (the
National Center for Health Statistics). This data is collected annually and made available
a few years later for the all who desire to conduct research on the area of health care
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utilization. This study used the 2015 version of NHAMCS, which is the most recently
available at this time.
The research questions relate to the role of provider type in predicting the
likelihood of an opioid prescription in the ED. The outcome variable was Opioid
Prescription (Yes/No) and the independent variable was Provider Type (the attending
physician, the resident or intern physician, the consulting physician, the nurse
practitioner, and the physician assistant). Logistic regression analyses was used to
address the main research question and the additional questions of possible interaction
between the covariates (Race and Payment Source) and the main IV (provider type) in
predicting the outcome, an OPR prescription.
Statistical Test
RQ1
RQ2

RQ3

Interpretation

Univariate Logistic Exp(B) of IV
Regression
Univariate Logistic Exp(B) of Interaction
Regression
Term,
X2 of model 2
Univariate Logistic Exp(B) of Interaction
Regression
Term,
X2 of model 2

Statistical
Significance
p-value, CI
p-value, CI
ΔX2, p-value
p-value, CI
ΔX2, p-value
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Chapter 4: Results
Introduction
The goal of this study was to investigate the nature of the relationship between
ED provider type and the rate of opioid prescription as it occurs in EDs across the United
States. In this chapter, I will report on the findings of the statistical analyses performed to
address the following three research questions:
RQ 1: Is there an association between provider type and rate of opioid
prescription in the ED?
RQ 2: Is the association between provider type and the rate of opioid prescription
influenced by the race of the patient?
RQ 3: Is the association between provider type and the rate of opioid prescription
influenced by the patient’s “expected source of payment”?
To answer the questions, I analyzed data from the CDC’s NHAMCS, as it
contains information relevant to opioid prescriptions by ED provider type and
encompasses the various characteristics of clients using ED facilities. The chapter is
divided into four main sections. The first section includes descriptive statistics for the
relevant variables (predictors and outcome). In the remaining three sections, I address
each of the research questions separately. The latest version of the SPSS software
application (SPSS 25) was used to conduct all data analyses.
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Descriptive Statistics
Demographic Characteristics
I opened the NHAMCS data set file in SPSS and saved it to my local hard drive.
The file contained 21,061 subjects and slightly more than 1,000 variables for these
subjects, 8.8% of whom were subsequently admitted to the hospital. These were filtered
from the file leaving 19,217 subjects. This file of only discharged visitors was saved as
the working file for the descriptive statistics and the logistic regression analyses in this
study.
As presented in Table 1, the working file contained a slightly higher percentage of
female patients (55.4%) than male patients (44.6%). With respect to race, the majority of
the subjects were White (72.9%), while 23.8% were Black and 3.3% were considered
neither White nor Black. According to Figure 7, the age distribution was bimodal, with
clients who were a year or younger having the highest frequency, followed by those in
the mid to late 20s with the second highest frequency peak. As seen in Table 1, the
largest age group were visitors between the ages of 25 and 44 years (29.9%); followed by
those between 45 and 64 years (21.1%) as the second largest. Children younger than 15
years of age accounted for 19.1% of the sample, and those between 15 and 24 years made
up 16.0% of all the ED visitors surveyed. The oldest group (over 65 years) totaled only
13.1% of the sample size. The age ranged from infants (less than a year old) to 93 years
of age, with an average age of approximately 36 years, with a standard deviation of
23.238.
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Figure 7. Histogram of AGE distribution.
The geographical distributions were divided into the four main regions of the
United States, listed in order of decreasing percentage: 34.2% from the South, 26.3%
from the Midwest, 19.9 % from the Northeast, and 19.6% from the West. These numbers
were based on the locations of the hospitals themselves and not necessarily the origin of
the patients. Of all the EDs included in this study, the majority were located in an area
considered metropolitan (83.6%) while less than a quarter were in nonmetropolitan areas
(16.3%). These numbers are reflective of the distribution of EDs across the United States.
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Table 1
Patient Demographics
Variable

Frequency

Percent

Cumulative
percent

Age
<15

3825

19.9

19.9

15 – 24

3068

16.0

35.9

25 – 44

5741

29.9

65.7

45 – 64

4057

21.1

86.9

65 – 74

1193

6.2

93.1

>= 75

1333

6.9

100.0

Female

10639

55.4

55.4

Male

8578

44.6

100.0

White

14004

72.9

72.9

Black

4578

23.8

96.7

Other

635

3.3

100.0

Northeast

3820

19.9

19.9

Midwest

5057

26.3

46.2

South

6580

34.2

80.4

West

3760

19.6

100.0

Metropolitan

16089

83.7

83.7

Nonmetropolitan

3128

16.3

100.0

Sex

Race

Region

Metro
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Predictor Variables
Independent variable: provider type. The main predictor variable under
investigation in this study was provider type, which refers to the different types of
medical professionals who are qualified to prescribe medications to patients visiting the
ED. Table 2 includes information on the number and types of providers in the analysis.
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Table 2
Prevalence of Provider Type
Variable

Frequency

Percent

NOPROVID
Yes

60

0.3

No

19157

99.7

Yes

16419

85.4

No

2798

14.6

Yes

1583

8.2

No

17634

91.8

Yes

1374

7.1

No

17843

92.9

Yes

17828

92.8

No

1389

7.2

Yes

1424

7.4

No

17793

92.6

Yes

2518

13.1

No

16699

86.9

Yes

902

4.7

No

18315

95.3

ATTPHYS

RESINT

CONSULT

RNLPN

NURSEPR

PHYSASST

EMT
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Of the five types, the attending physician (ATTPHYS) was the most common, with
85.4% of all the patients seen by this provider type. There was considerable overlap as
many patients were seen by more than one provider. A physician assistant (PHYASST)
was reported for 13.1% of the patients, a nurse practitioner (NURSEPR) for 7.4%, a
resident intern (RESINT) for 8.2%, and a consulting physician (CONSULT) visited 7.1%
of all the patients. There was a small number (0.3%) of patients for whom no provider
was reported (NOPROVID) and almost every patient was initially seen by an RN or LPN
(92.8%) or an EMT (4.7%) prior to a visit from the designated ED provider. The
information for each of these provider types were saved as separate dichotomous
categorical variables in the original data set. This format was preserved and used as is for
the logistic regression analyses in this study.
Potential moderators: payment and race. Two specific potential moderators
have been identified in this study- Payment source and race of each visitor. The payment
type variable (PAYTYPER) is based on six main categories of payment options recorded
for ED patients as well as those with no payment record. According to the data set (See
Table 3) the largest category of ED clients was made up of Medicaid or CHIP, which
combined for 33.3% of recorded payment source. Private Insurance was used by 29.6%
of the patients; Medicare used by 15.5%; 9.5% of the clients opted for Self-Pay; and only
0.8% had Worker’s Compensation. The rest of the patients was made up of those
designated as Charity (0.6%), Other (2.1%), Unknown (6.7%) and Blank (2.0%). This
variable though categorical in effect, was treated as scale based on a hierarchy as
assigned by data owners, i.e. the CDC statisticians. It was evaluated as both a categorical
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variable and an ordinal/continuous variable in this study.
The RACE variable was recorded several ways in the data, but only the variable
with three categories were used. These categories were White (Caucasian), Black
(African American and of African descent) and Other (those who were neither White nor
Black). The other variables recorded provided more specific details about ancestry and
ethnic origins, but those were not used as they did not add value to the study. The
distribution of the RACE variable was discussed previously (White 72.9%, Black 23.8%,
and Other 3.3% Other) in the ‘Demographics’ section.
Table 3.
Prevalence of Payment Type
Frequency
Valid

Missing
Total

Percent

Cumulative Percent

Private Insurance

5625

29.3

29.8

Medicare

2968

15.4

45.6

Medicaid/CHIP

6402

33.3

79.6

Worker's Comp

153

.8

80.4

Self-Pay

1820

9.5

90.0

Charity

113

.6

90.6

Other

399

2.1

92.7

Unknown

1367

7.1

100.0

Total

18847

98.1

Blank

370

1.9

19217

100.0

Confounding variables: pain and immediacy. The other confounding variables,
besides AGE and SEX, which were included in the model were those that reflected the
patient triage determination following evaluation in the ED. The two variables chosen
were the one measuring the patient’s pain scale (PAINSCALE) and the other recording
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the immediacy with the patient should be seen (IMMEDR). The first triage variablePAINSCALE variable was collected on numerical scale 0 to 10, as a record of the level
pain the patient was experiencing at the time of their visit. The ‘0’ represented no pain, a
‘3’ mild pain, a ‘5’ moderate pain, a ‘9’ severe or intense pain, and a ‘10’ represented
unbearable pain. The distribution for the pain scale was bimodal (See Figure 8), with the
largest group of patients (21.6%) reported no pain. The next two largest groups were
those with the of ‘8’ and ‘9’ pain rating, representing 13.3% and 13.2% respectively.
Despite this apparent skewness, approximately half (51.8%) were at ‘6’ or less and the
remaining values were above the average rating on the pain scale, approximating the
distribution as normal. The average pain rating was 5.13, with a SD of 3.668, with a
range between 1 and 10 (Table 4).
Figure 8
Histogram of PAINSCALE distribution
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The second triage variable was the IMMEDR, which recorded the immediacy
with which the patient should be attended to. It reflected the seriousness of their injury or
the intensity of the ailment and was based on the predesignated item triage levels. This
variable used a scale 0 to 5: 0=no triage, 1=immediate, 2=emergent, 3 = urgent, 4 =
Semi-urgent, and 5 = nonurgent. For the fields without usable data other numbers were
assigned: 7 = no triage conducted, -9 = blank, and -8 = unknown). This variable was also
used as a normally distributed, continuous variable in the logistic regression analyses,
with an average rating of 3.30 and a SD of 1.027 with a range from 1 to 5 (Table 4).
Table 4.
Descriptive Statistics of Confounder Variables
Mean

STD Dev

Min

AGE

35.68

23.238

0

93

PAINSCALE

5.13

3.668

0

10

IMMEDR

3.30

1.027

0

5

Figure 9
Histogram of IMMEDR (Immediacy) distribution

Max
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Dependent Variable: Opioid Prescription Outcome
The outcome variable was the first new variable to be created and this was done
using programming code provided by the CDC that allowed the counting of the opioids
(classified as “narcotic analgesic”) administered from all 30 of the columns where
prescribed medications were recorded. The code was based on the Multum Consumer
Drug Code coding system used in all clinic and hospital setting across the country.
Frequency analysis (Table 5) of this variable (Opioid_Pres), showed that 24.1% (4,623)
of the ED visitors (of the total N=19,217) were prescribed at least one opioid drug. Of
those receiving opioid prescriptions, 18.5% (3555) received only one opioid prescription;
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4.9% (937) received two opioid prescriptions, 0.64% (122) received three opioid
prescriptions, and only 0.05% (9) received four opioid prescriptions during their ED visit.
Table 5.
Opioid Prescription Distribution
Frequency

Percent

Cumulative Percent

No

14594

75.9

75.9

Yes

4623

24.1

100.0

# of Opioid
prescribed

1

3555

18.5

94.4

2

937

4.90

99.3

3

122

0.64

99.95

4

9

0.05

100.0

Total

19217

Bivariate Analysis
Pearson correlation. To investigate the possible correlation violations between
the confounders and the predictor variables, a series of bivariate analyses were
conducted. For the continuous variables (AGE, TRIAGE, PAINSCALE, and
PAYTYPER), a multivariate Pearson correlation test was conducted. The results
indicated that there was a significant correlation between all of the variables (p < 0.001)
with the exception of the correlation between AGE and IMMEDR (p=0.188). However,
despite statistical significance, all the correlations were weak with a less than 0.1
coefficient value. For example, the strongest correlation was between AGE and
PAYTYPER, but the Pearson coefficient measured at only -0.099, indicating a weak
negative correlation (Table 6).
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Table 6
Correlations of Continuous Variables
Correlations
AGE

Pearson Coefficient

AGE

IMMEDR

PAINSCALE

PAYTYPER

1

-.010

.028**

-.099**

.188

.001

.000

1

-.026**

-.046**

.002

.000

1

.071**

p-value
IMMEDR

PAINSCALE

PAYTYPER

Pearson Coefficient

-.010

p-value

.188

Pearson Coefficient

.028**

-.026**

p-value

.001

.002

Pearson Coefficient

-.099**

-.046**

.071**

p-value

.000

.000

.000

.000
1

Chi-square analysis of association. Even though, PAYTYPER is considered a
scale variable by the owners of the dataset, it was tested as both a categorical and as a
continuous variable for the purposes of correlation analyses. The Chi-square statistical
analysis of PAYTYPER was used to investigate its correlation with SEX and RACE. The
results (Table 7) indicated that there was a statistically significant relationship with both
RACE (χ2 = 510.264, p=0.00) and SEX (χ2 = 113.087, p=0.00). The measure of the effect
size, based on the Cramer’s V values (0.078 and 0.116), indicate both correlations can be
considered weak, but the latter being the strongest of all the bivariate associations
measured in this study (Kim, 2017).
The final set of bivariate associations tested were the correlation between the
provider types and all the confounders and the potential interaction variables (Table 8).
Here again the results indicated that most of the variables bore a statistically significant
association (p < 0.001). The exceptions were the association between SEX, and four of
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the provider-types (ATTPHYS, CONSULT, NURSEPR and PHYSASST) as well as the
association between RACE and PHYSASST, which were not statistically significant, and
with p > 0.05 in each these cases.
Table 7
Chi-Square Analysis of Association
χ2

p value

Cramer’s V

SEX

113.087

.000

.078

RACE

510.264

.000

.116

Variable
PAYTYPER

The majority of correlations were statistically significant, with most of the
covariates (AGE, RACE, PAYTYPER, IMMEDR and PAINSCALE) having an
associated with all five provider-types. Of the 30 paired associations tested, 26 were
statistically significant and 4 were not as seen in Table 8. The association between SEX
and the three provider-types- PHYASST, NURSEPR or CONSULT were not statistically
significant (p=0.283, p=0.725 and p=749 respectively), and similarly neither was the
association between RACE and PHYASST (p=0.834). All other correlations were
statistically significant with p-values less than 0.05, most of which were also less than
0.001.
Despite the extensive bivariate correlation demonstrated in the Chi-square
analyses results strength of the association was weak in all of the cases. The measures of
the respective Cramer’s V values for each these associated pair were less than 0.100,
except for two associations, that between the triage IMMEDR and ATTPHYS, and
IMMEDR and PHYSASST. In either case, the Cramer’s V values were only 0.142 and
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0.109, which is still considered relatively weak associations. Based on these results, the
assumption of no or very little multicollinearity among the covariates is met (Kim, 2017).
Table 8
Chi-Square Analysis of Association
χ2

p value

Cramer’s V

AGE

106.060

.000

.074

SEX

4.225

.040

.015

RACE

27.175

.000

.038

PAY

141.375

.000

.087

IMMEDR

386.716

.000

.142

PAINSC

26.209

.003

.044

AGE

84.069

.000

.066

SEX

12.227

.000

.025

RACE

121.221

.000

.079

PAY

45.755

.000

.049

IMMEDR

188.782

.000

.099

PAINSC

55.276

.000

.064

AGE

57.386

.000

.055

SEX

0.102

.749

.002

RACE

23.055

.000

.035

PAY

42.229

.000

.047

IMMEDR

155.506

.000

.090

PAINSC

20.954

.021

.039

AGE

27.128

.000

.038

SEX

0.124

.725

.003

RACE

41.393

.000

.046

PAY

45.909

.000

.049

Variable
ATTPHYS

RESINT

CONSULT

NURSEPR
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IMMEDR

110.632

.000

.076

PAINSC

24.148

.007

.042

AGE

37.200

.000

.044

SEX

1.153

.283

.008

RACE

0.363

.834

.004

PAY

42.585

.000

.048

IMMEDR

228.131

.000

.109

PAINSC

27.557

.002

.045

PHYSASST
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Results
Research Question 1: Provider Type Variation
RQ 1: Is there a significant association between ED provider type and rate of
opioid prescription in the ED?
As with all the research questions, a multivariate binary logistic regression, with
opioid prescription as the binary outcome, was used to answer this question. Addressing
the question involved a three-step process to the building the final model. In the first step,
the main confounders were ‘AGE,’ ‘SEX,’ ‘PAINSCALE,’ and ‘IMMEDR’ were tested
for their predictive relationship to the outcome. These four variables were tested to
determine which ones should be included in the final model. Based on this preliminary
test, it was determined that AGE (p =0.000) and PAINSCALE (p =0.000) were
statistically significant and should be included in the model (Table 9). The results
indicated that IMMEDR (p = 0.298) and SEX (p = 0.245), were not a statistically
significant predictor of opioid prescription outcome and they were excluded in
subsequent models (Table 5).
Table 9.
Odds Ratio of Possible Confounders for likelihood of an Opioid Prescription
95% C.I.
Odds Ratio

p-value

Lower

Upper

AGE

1.018

.000

1.016

1.020

SEX

1.051

.245

.967

1.143

PAINSCALE

1.315

.000

1.297

1.333

IMMEDR

1.005

.298

.995

1.016

Constant

.033

.000
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According to this model, every year increase in age corresponds to a 1.8%
(OR=1.018; 95% CI 1.016-1.020) increased likelihood of an opioid prescription when
controlling for SEX, PAINSCALE, and IMMEDR. And for every increase in unit pain,
there is 32% (OR=1.315; 95% CI 1.297-1.333) increased likelihood of an opioid
prescription, when controlling for AGE, SEX and IMMEDR.
In the second step in building the model, a second preliminary multivariate
logistic regression (MLR) was performed. This MLR model contained only the five
provider-type as predictors and the opioid prescription outcome. In this model, without
adjustment of the covariates, (Table10), three of the five provider-type proved to be
statistically significant predictors of the outcome, all with p < 0.001. According to Table
6, there was a statistically significant relationship between Attending Physician (60%
increase), Nurse Practitioner (35% increase) and Physician Assistant (40% increase).
Two of the provider-types did not demonstrate a statistically significant relationship with
the prediction outcome, RESINT (p=0.555), and PHYSASST (p=0.159).
Table 10.
Odds Ratio of Provider-Types for the likelihood of an Opioid Prescription
95% C.I. for EXP(B)
Lower
Upper
1.435
1.793

Odds Ratio
1.604

p-value
.000

RESINT

.963

.555

.849

1.092

CONSULT

1.095

.159

.965

1.242

NURSEPR

1.348

.000

1.178

1.543

PHYSASST

1.399

.000

1.266

1.546

Constant

.196

.000

ATTPHYS
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The third and final step in answering the first research question, was the final
construction of the comprehensive model that included all the predictor variables:
provider-types, along with the confounders AGE, and PAINSCALE. Both AGE and
PAINSCALE were remained statistically significant when controlling for the provider
types and there was an overall statistical difference in the probability of the providertype. However, in this new adjusted model (Table 11), the three provider types that were
significant predictors were ATTPHYS, CONSULT and PHYSASST when controlling for
all other variables. According to this model, a patient seen by an Attending Physician had
a 50% (OR=1.491, 95% CI 1.297-1.715), by Consultant Physician had a 32%
(OR=1.318; 95% CI 1.127-1.542) or by a Physician Assistant had a 32% (OR=1.315,
95% CI 1.162-1.488) higher probability of being prescribed an opioid medication,
compared to not being seen by each of these provider types. Based on these findings, the
null hypothesis is rejected in favor of the alternative hypothesis: That there is a
significant association between ED provider-type and the probability of an opioid
prescription.
Table 11.
Odds Ratio of Provider Types for Opioid Prescription controlling for Age and Pain
95% C.I.
Lower
Upper
1.016
1.020

Odds Ratio
1.018

p-value
.000*

PAINSCALE

1.306

.000*

1.298

1.335

ATTPHYS

1.491

.000*

1.297

1.715

RESINT

.976

.767

.834

1.143

CONSULT

1.318

.001*

1.127

1.542

NURSEPR

1.167

.076

.984

1.383

AGE

120
PHYSASST

1.315

.000*

1.162

1.488

Research Question 2: Provider Type and Race
RQ 2: Is the association between provider type and the rate of opioid prescription
influenced by the race of the patient?
H02: The association between provider type and the rate of opioid prescription is
not dependent by the race/ethnicity of the patient.
Ha2: The association between provider type and the rate of opioid prescription is
dependent by the race/ethnicity of the patient.
This question attempts to determine if the RACE variable influences the
relationship between provider type and opioid prescription. Published research confirms
the role ‘Race’ as having a predictive relationship on the probability of opioid
prescription. Firstly, the predictive measure of RACE was tested based on the current
data set, and the published findings were confirmed by this analysis. A univariate logistic
regression with RACE as the independent variable and opioid prescription as the
dichotomous outcome, demonstrated that it was statistically significant. Patients from
both race classes, Black and ‘Other,’ were shown to have a reduced likelihood, relative to
White patients, of receiving an opioid prescription. However, only the reduced likelihood
(20% less) for Black patients (O.R. = 0.799; 95% CI 0.737-0.866) was statistically
significant (see Table 12).
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Table 12.
Odds Ratio of RACE for Opioid Prescription Probability
95% C.I.
Lower
Upper

Odds Ratio

p-value
.000

RACE1 (Black)

.799

.000

.737

.866

RACE2 (Other)

.884

.202

.732

1.068

Constant

.335

.000

Reference (White)

When combined with the other confounders from research question #1, RACE
remained statistically significant. Blacks had a slightly less (16% reduced) likelihood
(OR=0.836; 95% CI 0.770-0.907), compared to Whites, of being prescribed an opioid,
when controlling for AGE and PAINSCALE (See Table 13). Both the odds ratio and
statistical significance of the other variables (AGE and PAINSCALE) remained the same.
Table 13.
Odds Ration of Race for Opioid Prescription controlling for PAIN and AGE
95% C.I.
Lower
Upper
1.016
1.020

Exp(B)
1.018

p-value
.000

RACE

.836

.000

.770

.907

PAINSCALE

1.316

.000

1.299

1.335

Constant

.045

.000

AGE

When the RACE variable was added to the model that included the providertypes, and all the other confounders, RACE remained statistically significant. However,
according to Table 14, the addition of RACE did have an effect on the predictive
relationship of the provider-types that showed a statistically significant relationship with
the outcome. The probability of an opioid prescription from an Attending Physician was
now at 61% increase (OR=1.613, %95 CI 1.119-203.5), and the predictive relationship of
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the other two provider types (formerly significant) were no longer statistically significant.
However, despite the persistence of the statistically significance of Attending Physician,
the interaction between this variable and RACE (and the other previously significant
variables) was not statistically significant. In this case the findings indicated that the null
hypothesis should not be rejected as there appears to be no moderation interaction of
RACE on the predictive capacity of the provider-types.
Table 14.
Odds Ratio of RACE, Provider types, AGE and PAINSCALE for Opioid Prescription
95% C.I.
Upper
1.020

Exp(B)
1.018

p-value
.000

Lower
1.016

RACE

.852

.216

.662

1.098

PAINSCALE

1.319

.000

1.300

1.337

ATTPHYS

1.613

.010

1.119

2.325

RESINT

1.019

.814

.869

1.195

CONSULT

1.264

.254

.845

1.891

NURSEPR

1.176

.062

.992

1.394

PHYSASST

1.073

.672

.775

1.486

ATTPHYS by RACE

.943

.655

.728

1.221

CONSULT by RACE

1.035

.811

.780

1.374

PHYSASST by RACE

1.175

.174

.931

1.483

Constant

.029

.000

AGE
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Research Question 3: Provider Type and Payment Type
RQ 3: Is the association between prescriber type and the rate of opioid
prescription influenced by the patient’s “expected source of payment”?
H03: The association between prescriber type and the rate of opioid prescription is
not influenced by the patient’s “expected source of payment”.
Ha3: The association between prescriber type and the rate of opioid prescription is
influenced on the patient’s “expected source of payment”.
The second moderation variable investigated was that of the type of payment
(PAYTYPER) used by the patients to pay for the services received during their visit to
the ED. PAYTYPER was tested for possible interaction with the provider-type variables
and their relationship with the opioid prescription outcome. Prior to including it as an
interaction variable, PAYTYPER was tested alone, as a categorical variable, in a
univariate logistic regression analysis and it was determined to be statistically significant
(p = 0.000) overall. In this univariate analysis (Table 15), the reference category was
Private Insurance, and it showed that those using Medicare (0.5% increase), Worker’s
Comp (46% increase), and Self-Pay (11% increase) were more likely to be prescribed an
opioid compared to those using Private Insurance. On the other hand, Medicaid/CHIP
(30% decrease) users were less likely of being prescribed opioids. The odds ratio for the
other types of payment categories (NOCHARGE, OTHER, UNKNOWN), relative to
Private Insurance, was not significantly different.
Table 15.
Odds Ratio of PAYTYPER (categorical) for Opioid Prescription
95% C.I.
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Odds Ratio

p-value
.000

Lower

Upper

Medicare

1.054

.000

.953

1.165

Medicaid/CHIP

.701

.307

.643

.763

Workers Compensation

1.455

.000

1.036

2.044

Self-Pay

1.112

.030

.988

1.252

No Charge/Charity

.931

.077

.605

1.433

Other

.871

.746

.686

1.106

Unknown

.826

.257

.718

.950

Constant

.354

.007

PAYTYPER

When the variable PAYTYPER was added (as an ordinal/continuous variable) to
the multivariate analysis (Table 16) containing the other confounders, it remained
minimally statistically significant. For every unit change in payment type, there was
approximately a 3.6% (OR=0.964; 95% CI 0.944-0.984) decrease in likelihood of an
opioid prescription, when controlling for AGE, RACE, PAINSCALE. The OR and the pvalues of all other confounders remained the same.
Table 16.
Odds Ratio for RACE, AGE, PAINSCALE and PAYTER for Opioid Prescription
Exp(B)
.964

p-value
.001

Lower
.944

95% C.I.
Upper
.984

AGE

1.018

.000

1.016

1.020

RACE

.844

.000

.777

.916

PAINSCALE

1.317

.000

1.299

1.336

Constant

.051

.000

PAYTYPER

In the final model, adding PAYTYPER along with the provider-types and the
other covariates, PAYTYPER and the other confounders maintained a statistically
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significant relationship with the outcome (see Table 17). Of the provider types, only
ATTPHYS (p=0.000) and PHYSASST (p=0.001) remained statistically significant,
CONSULT failed to reach significance (p=0.106). However, the coefficients for the
interaction term ATTPHSxPAYTYPER was statistically significant (p=0.014), but the
other interaction terms were not. For patients seen by an Attending Physician, the
probability of opioid prescription decreases by 2.9% for every unit change in payment
type. From these findings it can be concluded that the null hypothesis can be rejected, and
that Payment Type does influence the relationship between Provider Type and the
probability of an opioid prescription
Table 17.
Comprehensive Model of Odds Ratio (RACE, AGE, PAINSCALE, all Provider Types, and
possible Interaction variable) for Opioid Prescription
95% C.I.
Lower
Upper
1.016
1.020

Odds Ratio
1.018

p-value
.000

PAINSCALE

1.317

.000

1.299

1.335

ATTPHYS

1.567

.000

1.351

1.818

CONSULT

1.254

.106

.953

1.652

PHYSASST

1.404

.001

1.143

1.725

ATTPHYS by PAYTYPER

.971

.014

.948

.994

CONSULT by PAYTYPER

1.014

.747

.933

1.102

PAYTYPER by PHYSASST

.972

.320

.918

1.028

Constant

.025

.000

AGE

Summary
Several logistic regression analyses were carried out to answer the respective
research questions. Before answering the main questions, the role of several confounders
(AGE, SEX, PAINSCALE, and IMMEDR) were first investigated for their relationship
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with the opioid prescription outcome. The results indicated that SEX was not statistically
significant when controlling for the other factors and was not included in subsequent
models. For the first research question, the predictive relationship between the providertype and an opioid prescription outcome was tested. The results indicated that in the
model containing all provider types, there was a statistically significant predictive
relationship between opioid prescription and three of the provider types. This statistically
significant relationship persisted after controlling for AGE and PAINSCALE values (see
Table 11). Patients seen by an Attending Physician (50% increase), Consulting Physician
(32% decrease) and Physician Assistant (32% increase) all had an increased likelihood of
receiving an opioid prescription, relative to not being seen by these provider types.
The second and third research questions investigated the impact of two possible
moderation interactions. The second question dealt with the RACE variable, which
proved to be a significant predictor, with Blacks being 28% less likely to receive opioid
prescription compared to White patients. However, RACE did not have an impact on the
relationship between the Provider Type and the outcome, as the odds ratio and
significance remained the same after the addition of RACE (see Table 14). The third
question looked at the role of PAYTYPER, and similar to RACE, this variable was
predictive of an opioid prescription. Relative to Private Insurance, patients using
Worker’s Compensation, Self-Pay and Medicare were more likely to be prescribed an
opioid (46%, 11%, and 5% respectively). Additionally, when PAYTYPER was
introduced into the comprehensive model, which included the provider types, the
interaction between Attending Physician and Payment Type was statistically significant,
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indicating that this variable does influence the relationship between Provider Type and
the probability of an Opioid prescription.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The opioid use disorder is one the most serious aspects of the widespread abuse of
prescription drugs in the United States. This problem has been addressed from several
angles by those in the public health arena. One of the areas of focus is the variation in
prescription rates with regards to opioid analgesics. In this study, I focused on the
variation in prescription rates as seen in the many EDs across the country. Public health
experts have implicated this variation in the problem of excess opioid flooding the
market.
There are many factors involved in the probability of an opioid prescription, and
several researchers have looked at various patient characteristics (i.e. race, gender, locale,
SES, etc.; see Hui Chen, Hedegaard, & Warner, 2014; Joynt et al., 2013; Mcdonald et al.,
2012; Singhal et al., 2016; Tamayo-Sarver et al., 2003). However, more recent
researchers have focused on the role of the providers who make prescription decisions
and the many provider specific characteristics involved (see Mazer-Amirshahi et al.,
2016; Ringwalt et al., 2015; Sasson et al., 2018; Smulowitz et al., 2016). These few
studies have all been limited in scale and scope, with relatively small samples sizes.
Nonetheless, they have documented prescription rate variation among providers, and they
have shed light on a possible source of and potential solution to the opioid prescription
dilemma.
In this current study I looked more closely at the role of provider type in opioid
prescription variation in the ED setting. The availability of the NHAMACS data set
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facilitated this study, which was on a larger scale than previous studies. Not only is this
data set a nationwide survey, it contains an excess of information on each ED visit (over
1,000 variables), including all the providers seen and all the drugs prescribed, as well as
other demographics such as age, gender, and painscale score. For this study, I conducted
a quantitative analysis of the most recent and available data, the 2015 version of the
NHAMACS data set, to answer the study’s three research questions.
I designed the research questions to evaluate to what extent, if any, provider type
was related to the likelihood of an opioid prescription. The dependent variable was the
probability of an opioid prescription, for which I created a dichotomous variable (1 =
opioid prescription, 0 = no opioid prescription) from the analysis of all the prescription
drug data available for each visit to the ED. The dependent variables were the five
different types of ED providers (attending physician, consultant physician, resident intern
physician, nurse practitioner, and physician assistant) who were associated with the
patient’s prescriptions. These variables were also measured dichotomously (1 = specific
provider seen, 0 = specific provider not seen). The other ED provider types (registered
nurse, licensed practical nurse, and emergency medical technician) with no prescribing
privileges were not included in the analysis.
In order to elucidate the extent of the association between the dependent variable
(probability of an opioid prescription) and the independent variable (provider types), I
performed a quantitative analysis to build a predictive model. The outcome variable,
being dichotomous, required a logistic regression analysis. Other covariates were added,
after being tested and their statistically significant association confirmed. Following the
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descriptive analyses, the univariate and multivariate logistic regression analyses
generated predictive models that combined the predictors with the outcome to answer the
three research questions.
Interpretation of the Findings
Descriptive Statistics
Before I undertook the specifics of the logistic regression analyses, I generated a
number of descriptive statistics. All analyses (descriptive and inferential) were conducted
after filtering out those who were eventually admitted into the hospital as a result of their
visit. This was done to exclude hospital-administered medication from the analysis, as the
focus was on discharge prescription. The resulting data revealed that there was relative
balance across the genders (55.4% females), with only slightly more males presenting to
the ED among those discharged. The distribution of the races was unequal, as was
expected based on the national distribution; however Blacks made up 23.8% of the ED
visitors’ population (compared to Whites, 72.9%, and Other, 3.3%) even though they
only make up approximately 13% of the general population. Both the gender and age
distribution were similar to those reported in previous national ED studies (Kea, Fu,
Lowe, & Sun, 2016b; Mazer-Amirshahi et al., 2014; National Center for Health
Statistics, 2017).
The spread in age was more complicated, with the probability distribution
revealing a bimodal distribution. The patients under the age of 1 (babies) and toddlers
made up the group with the highest frequency, and the rest of the sample made up
another group, peaking at around age 22 and 28 years. Previous researchers either
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restricted their analysis to adults (more than 18 or 21 years old) or grouped all those
younger than 18 years into one category (Kea et al., 2016b; Kilaru et al., 2014; National
Center for Health Statistics, 2017).
The main variable in this study was the probability of opioid prescription, which
was measured dichotomously. The overall average percentage receiving an opioid
prescription at discharge was 24.1% of all ED patients. In other smaller studies of note,
researchers reported different opioid prescription rates; in one study, the authors found
only a 14% opioid prescription rate in the EDs across three military hospitals (Ganem et
al., 2014). In a multicentered study in 2012 consisting of 27,516 patients, the opioid ED
prescription rate was 17% (Hoppe et al., 2015). But these studies were not on a national
level, present study’s percentage (24.1%) is down from the 28% in 2010-2011, but still
not as low as the 20% in 2000-2001 (Mazer-Amirshahi et al., 2016) or the average 18.7%
during 2006 to 2010 period (Kea et al., 2016b).
For the main independent variables of interest, provider type, an overwhelming
majority of the patients were seen by an attending physician (85.4%). The other provider
types saw no more than 10% of the sample of patients each (resident intern: 8.2%, a
consulting physician: 7.1%, a nurse practitioner: 7.4%, and physician assistant: 4.7%). In
a previous study conducted at a single institution and with the providers divided into two
categories, MDs and NPs/PAs, researchers recorded comparable percentages: 80% and
20%, respectively (Smulowitz et al., 2016). Similar ratios were recorded in a study that
included EDs of three tertiary care military hospitals: MDs, 79%, and PAs, 19% (Ganem
et al., 2014). However, the authors of these studies used chart patient-specific data and
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were able to associate a specific provider with each patient and each opioid prescription.
In this present study, even though the percentages are comparable to previous findings,
there was considerable overlap as patients sometime saw two and three ED providers
during the same visit; findings should therefore be interpreted with caution.
Research Question 1: Provider Type Variation
The first logistic regression analysis revealed that the probability of an opioid
prescription was dependent on age as was reported previously (Dorn, Meek, & Shah,
2011; Weiss et al., 2014; Yacisin et al., 2018). Additionally, as should be expected, the
level of pain (PAINSCALE) also had a significant impact on the frequency with which an
opioid was prescribed. Previous researchers did not include level of pain as a covariate;
they either restricted their study to a specific pain-related condition (e.g. low-back pain or
abdominal pain; Dorn et al., 2011; Mazer-Amirshahi et al., 2014; Patel & Afshar, 2017)
or categorized a patient’s pain based on predetermined diagnostic categories (R.
Dickason et al., 2015; Joynt et al., 2013; Kea et al., 2016b; Prunuske et al., 2014).
Interestingly, in the analysis data disclosed that 7.5% of those with a reported pain level
of zero were recorded as having been prescribed an opioid analgesic. This is possibly due
to an error in documenting the patient’s actual pain score or failure to update the
information after the pain level changed.
In this data set, neither the effect of gender nor that of triage level (IMMEDR)
proved to be statistically significant. In other research, where gender was reported as
significantly different, the effect sizes were small- 53% of male vs 42% female, (Kea et
al., 2016a) or male 50% vs female 47 % (Hoppe et al., 2015). Like in this present study,
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the reports of significant differences were based on unadjusted analysis, and once
adjusted, the gender difference was no longer statistically significant (Dorn et al.,
2011)(R. M. Dickason et al., 2015)(Gebauer et al., 2017). Similarly, as with the gender
variable, when the model was adjusted for pain score, the measure of triage was no
longer statistically significant. These are both positive findings, indicating that there is
not gender disparity in the opioid prescribing rates, and that the rates of prescribing this
pain-medication are associated more strongly with pain levels than with triage measures.
ED provider type variation. In the comprehensive model developed from this
data set, the three provider-types with statistically significant predictive association, all
with an increased probability of an opioid prescription, were Attending Physician (60%),
Consultant Physician (35%) and Physician Assistant (40%). It is worth mentioning, that
one other provider-type had a potentially significant relationship to the outcome, that of
Nurse Practitioner. The relationship was not significant in the univariate formula, but
when adjusted for age, the p-value was markedly reduced from 0.261 to 0.068, almost
approaching significance (see Table 18). Similarly, with that of Consultant Physician,
which originally was marginally statistically insignificant in the univariate model,
became unquestionably significant (p=0.000) when controlling for pain. These results
suggest a difference in the influence of the covariates, age having a greater impact
(relative to pain) on the Consultants, and inversely, pain being more critical (relative to
age) to the Nurse Practitioner with respect to prescribing opioids. A previous pilot study
on the factors affecting ED providers’ opioid prescription decisions similarly reported
that patients’ pain level was higher in the order of importance for advance practice
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providers (NPs/PAs) than for Resident and Attending physicians. On a scale of 1-5,
attendings ranked pain 2.99 on average and 2.89 for Residents, but 3.60 for the NPs/PAs
group (Pomerleau et al., 2016).
Ultimately, in the final model for the current analysis, the Nurse Practitioner
variable was excluded and that of the Consultant retained, as was warranted by the
corresponding p-values after adjusting for both Pain and Age (See Table 1). When
considering these values, it is important to bear in mind the overlap in the data (patients
seen by more than one provider) and that attending physicians (85.4%) saw between 12
to 6 times as many patients that all the other types of providers (7.1% and 13.1%). This
overlap introduces a measure of correlation that serves to dilute the accuracy of the
results, but it should be noted that these odds values were approximately the same in the
univariate logistic regression and when adjusted for age and painscale.

Table 18
Adjusted and Unadjusted p-values for Nurse Practitioner and Consultant Physician
Unadjusted

Age

Pain

Race

Age + Pain

Nurse
Practitioner

0.261
(1.074)

0.068
(1.125)

0.278
(0.918)

0.221
(1.081)

0.620
(0.961)

Consultant
Physician

0.072
(1.122)

0.593
(1.035)

0.000
(1.418)

0.050
(1.134)

0.000
(1.340)

In most of the studies on the variation in opioid prescription rates in the ED,
researchers used categorizations other than the different provider types used in the current
study. In most studies researchers looked at only MDs, comparing experienced vs
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inexperienced emergency physicians; or divided the providers into low-intensity
prescribers versus high-intensity prescribers. Few studies stratified based on provider
types, like the military two-hospital study, where researchers found that the PAs were
more than twice as likely to prescribe opioids (relative to non-opioids) than MDs were,
with opioids being 55% and 23% of their respective total analgesic prescriptions (Ganem
et al., 2014). Those results echo that of the national multi-year trend (2005 to 2015) study
on opioid prescriptions rates, where researchers found that opioid prescriptions by MDs
and PAs increased by 61% on average, but the increase was twice as much for Nurse
Practitioners, increasing 116.7% over the same period (Yang et al., 2018). Another
related study of the opioid prescription for Medicare patients found an overall significant
rise in opioid prescriptions, but the increase was greater for by the advanced practice
practitioners (APPs) compared to the that for the MDs (Axeem, 2018). These results
confirm the increasing roles and responsibilities for APPs, not just in medicine in general
but in prescribing of medication, particularly opioids.
Research Question 2: Provider Type and Race
Race was found to be a significant predictor of the probability of an opioid
prescription with Blacks (20% less unadjusted or 17% less adjusted) less likely to be
prescribed an opioid and this is line with many of the previous studies. This is congruent
with the findings in other study (Singhal et al., 2016) (Joynt et al., 2013) (R. Dickason et
al., 2015). One of the earliest on this topic, reported that despite the trending (1993 to
2005) increase in opioid prescription in the EDs, racial difference persisted, with the
increase for Whites going from 31% to 40%, while increasing from 23% to 32% for
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Blacks (Pletcher, 2008). A later study looking using NHAMCS data from 2007 to 2011,
found that the racial/ethnic variation in opioid prescription rate had worsened, with
Blacks being less likely (43% for abdominal pain and 33% for back pain) to receive an
opioid prescription compared to Whites and other races (Singhal et al., 2016).
Additionally, the racial disparity between Whites and Blacks for the frequency of opioid
prescription worsened as the pain intensity increased, e.g. back pain (48% vs 36%,
respectively), headache (35% vs 24%), abdominal pain (32% vs 22%), and other pain
(40% vs 28%) (Pletcher et al., 2008). The many studies exposing and confirming the
racial disparity over the years may have something to do with the reduced percentage
numbers reported in the current analysis, nonetheless the disparity persists.
When added to the model, race has an effect on the strength of the relationship for
two of the providers (N.P. and P.A.), but not the other Attending. For the N.P., the odds
decreased from 35% to 17% and the new p-value failed to reach significance (p=0.062),
while in the case of the PAs, the odds decreased to almost one 1 (OR=1.073), and it was
no longer statistically significant (p=0.672). Since the interaction terms for each of three
provider types were not statistically significant the null hypothesis was not rejected,
nonetheless that does not rule out the effect of RACE on the relationship between these
provider types and the outcome. Maybe the effect of race is not one of moderation but
one of mediation, and this would be confirmed or refuted by a different type of analysis.
Racial disparity in US healthcare system is been studied and reported on for
decades, and this disparity has been reflected in the treatment of pain and specifically in
the administration of analgesics (Chen et al., n.d.; Committee on Advancing Pain
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Research, Care, 2011; R. M. Dickason et al., 2015; Jeffery et al., 2018; Maly &
Vallerand, 2018). As in other areas of healthcare, there have been many speculations as
to the cause of this racial disparity, including physicians being majority White and
empathizing best with patients who look like them; to the minimizing of the pain being
reported by Black patients; or reduced ability of providers to identify signs of potential
abuse in White patients (Chen et al., n.d.). Interestingly, another study of 5.2 million
opioid prescriptions (Optimum Labs Data Warehouse 2009-2015) found similar results in
the racial disparity, but when the prescriptions were stratified by types, Blacks more
likely than other racial groups to receive the short term, lower dose prescriptions while
Whites received longer term, higher dose opioid prescriptions (Jeffery et al., 2018)(Joynt
et al., 2013). Another study reported on the “reverse disparity” in the offering of opioid
monitoring and treatment strategies, Whites being more frequently exposed and directed
to treatment once opioid abuse disorders are suspected (Beker et al., 2011). Despite
reports on the racial disparity, the racial disparity in prescription and treatment, remains
correlated with the predominance of Whites in long term use and even abuse of opioids
(Barnett et al., 2017; (Hui Chen et al., 2014; National Academies of Sciences,
Engineering, and Medicine, 2017).
Research Question 3: Provider Type and Payment Type
One of measures that is always difficult to assess is that of the patient’s
socioeconomics, as that type of data is not usually collected directly in these types of
surveys. Most studies have used neighborhood-level socioeconomic status as defined by
the patient’s zip code (Hudley et al., 2014)(Gebauer et al., 2017), but this is not always a
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reliable indicator as many neighborhoods are of mixed of socioeconomic. Like other
studies, this study used payment source as a pseudo-SES measure to evaluate the
predictive relationship between the opioid prescription outcomes. The idea of SES being
reflected in payment source is not new, as other studies have used it and found similar
variation in prescription rates based on this pseudo-SES classification (Dorn et al., 2011;
Singhal et al., 2016; Sites et al., 2014).
The analysis of the NHAMCS 2015 data found that there was a predictive
relationship between this pseudo-SES and the probability of an opioid prescription.
Worker’s Compensation users had the highest increased (45.5% relative to Private
Insurance) all the three payment types with an increased likelihood. The other two were
Medicare and Self-Pay, but the effect sizes were marginal (5.4% and 11.2%,
respectively). The remaining payment types had reduced likelihoods, and the differences
were not statistically significant. Worker’s Compensation being associated with a higher
likely to obtain the prescription medicine compared to other types of insurance or
payment source was reported previously. Hoppe et al. reported that, when Worker’s
Compensation was used as the reference, all other payment types had a reduced odds of
prescription opioid, Federal/Government 0.70; Medically Indigent 0.58; Private 0.56, and
Self-Pay 0.24 (Hoppe et al., 2014).
Other researchers have also reported on the relationship between opioid
prescription rates and socioeconomic status measured by insurance type. But most of
these studies used three or four major groupings that included Private Insurance,
Government/Public Insurance (Medicaid, Medicare separately or together), and Other (no
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insurance, charity, etc.). Although the results of these study would depend on whether a
particular diagnosis was being evaluated or opioid prescriptions as a whole. In general,
these studies found that patients with public/government (Medicaid or Medicare)
insurance were more likely to be prescribed opioids compared to those with private
insurance (Shah et al., 2015)(Hoppe et al., 2017)(Joynt et al., 2013)(Dorn et al., 2011).
These findings were in agreement with those that used neighborhood socioeconomic
measures, and found that low nSES was associated with a higher probability of opioid
prescription compared to high nSES, but the racial disparity persisted in either
communities (Gebauer et al., 2017) (Prunuske et al., 2014)(Maly & Vallerand,
2018)(Joynt et al., 2013).
Findings Related to the Conceptual Framework
According to SIT, human behavior can be explained by underlying thoughts and
subconscious motivations, based mainly one’s interpretation of social symbols (Aksan,
2009). In the field of healthcare, SIT enlightens the nature of the relationship between
patients and their healthcare providers, and the many factors that govern these unique
social interactions. SIT guided research has revealed the importance of the provider’s
work priorities and their perceptions of their patients as being utmost concerns, especially
in the ED where the interactions are shorter and more intense (Battjes, 2009). In these
setting, prescription decision making is influenced by the established guidelines and
policies, but also by the providers’ unconscious notions of the as well. Insight into these
unconscious notions are needed to provide guidelines that prevent their adverse effects.
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The findings in this study substantiates the prescription rate variation based on
provider types as is presumed by idea inherent in SIT. The different provider types,
though all with similar objectives, have differences in their training, their approach, their
attitudes and their practice of healthcare (Maycock, 2015). According to SIT it is these
differences that will have an impact (directly or indirectly) on their health care decisions,
which in turn affects their prescription decision making and ultimately their prescription
rates (Byrne & Heyman, 1997). These differences however have the potential to put
patients at risk for undertreatment or overtreatment when it comes to their pain related
ailment (Singhal et al., 2016)(Maycock, 2015). It is therefore important that these
differences are studied and addressed so that providers can be confident that their actions
are in no way jeopardizing the health of those they are serving.
There are a variety of factors involved in the ED prescription rate variation for
opioids. Previous research findings have reported on prescription rate variation among
the same types of providers and on variation based on race, age, experience, location, etc.
Studies that did not divide the providers among the different types, found variations that
were based on other physician characteristics. Uncovering the traits that have the largest
impact on prescription variation can be important to the practice of pain management
specifically and to medicine as a whole. Prescription decisions are complicated for
providers, and the chaos in the ED and the stigma surrounding opioids all make for a
difficult situation. Providers are often caught in the middle of patient satisfaction and
evaluation of them and the policies put in place by those in charge (Sinnenberg et al.,
2017). Policies informed by sound reliable research can make things easier for them and
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improve the experience for provider and patient, both in the short and long term. The
undisputable impact of race and socioeconomics on prescription rate, even after
controlling for age and painscale are clear implication that biases are involved.
Uncovering and acknowledging these biases are important to fair and balanced treatment
for all patients. And confronting these biases may be critical to minimizing the
contribution of the providers to the excess of opioids exposure that puts patients at risk
for abuse in the future.
Limitations of the Study
This study did find that there were statistically significant differences between the
various provider types and the rate of opioid prescription but there are many limitations
to the generalizability of the findings. One of the biggest limitations of this type of study
is the nature of the data. There is considerable overlap in the variables of interest,
provider type. As such it is impossible to determine which provider actually prescribed
the medication and the analysis is purely one of association. Additionally, the diagnosis
variables also overlap, with many patients many having more than one of the over 25
different main diagnoses, making it challenging to include ‘Diagnosis’ as a variable and
thereby control for it.
The effect of both race and payment type were evaluated and the results indicate
that both have a predictive relationship to the outcome. However, based on this restricted
analysis of prescription rate, only payment time was found to have a significant
interaction with the provider type. Other studies have found that race significantly
correlated to socioeconomics and consequently to the payment source only more a
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detailed data set, and more specific statistical analyses will unravel the nature of the
relationship of each to the outcome. Accounting for the possible violations of the
assumptions of limited collinearity may provider more reliable results.
One of the assumptions of this study is that an increased prescription rate
implicates that provider type as contributing to a problem of over prescribing opioid.
However, as other studies have shown, those who prescribe more frequently may actually
be more closely following protocol. No comparison of opioid analgesics relative to nonopioid analgesics no information on the appropriateness of the prescription. Interestingly,
a small study on the effect of state drug monitoring program found that while residents
prescribing habits were influenced by that of their training attendant, one third of the
attending physicians who consulted the program resulted in an increase in the quantity or
amount of opioid drugs prescribed (Feldman et al., 2012). The assumption was that the
Attendings felt safer to adjust their prescription habits to meet the clients need after
realizing that it was sanctioned in the official guidelines.
As this analysis did not account for the quantity or dosage of the opioid
prescription (information not contained in this data set), there is no determination of that
effect relative to overall rate. Also, since there is no data on individual providers or
inclusion of detailed diagnosis, it is difficult to make more substantial inferential analysis
of the appropriateness or inappropriateness of the prescriptions (Kea et al., 2016b). This
study did not identify individual patients, but instead use ED visits as the unit of measure,
and it did not distinguish between who received on opioid prescription or several (up to
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four) during the visit for any possibility of follow-up. This national data is suitable for
determining average effect, but not for the more specific type determination.
Recommendations
The findings in this study is the first of its kind in that it provides a large-scale
perspective (on a national level) on the results of opioid prescription variation based on
provider types. It also confirms the role of acknowledged covariates age, race, painscale
and payment types, and although the strength of the data lies its size, the results must be
inferred with caution. Working with such a large data set can make it difficult to detect
the nuances that may lay in the various categories of the variables measured. The findings
are based on national averages and should be taken as such. The current results are
recommended for comparing past and future national averages and for generating general
insights into the nature of the opioid epidemic prescription rate problem.
There are many limitations to this study, but it does provide some direction for
future research. The area of opioid rate variation is complex and even when zeroing in on
the specifics of provider type variation, there are many issues to be considered. To make
the findings more specific, the provider type analyses can be based on a number of
different strata, including region, state, type of hospitals or institutions that house the
various EDs, size of institution, etc. Other ways that the data can be divided includecomparing patients’ demographics (different age groups, diagnosis, race, class, etc,) or
time of week (weekday vs. weekends), or daytime vs. night time or other classifications
that allow a deeper understanding into of nature of the relationships detected.
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Other limitations to the study included the lack of detailed information for
provider or patient. Unfortunately, the data collected in the NHAMCS does not provide
any information about individual provider characteristics or specifics of the opioid
prescription received by patients. Future research is needed into these aspects and for this
data other than administration survey data are needed. For a thorough analyses of the role
of provider characteristics, information about the provider demographics (age, sex, race
and duration of experience) is required, as preliminary research has indicated that this
may be more important than provider type (Bartley et al., 2015). For the ED providers,
maybe the difference is not in the provider-types but in the type of training and
background or the number of years of experience or some other feature or characteristics
that affects their prescription decisions. But this can only be assessed using data that
collected the relevant information.
Similar to the issue of provider type classification is that of absence of
information about the class of opioid prescribed - without information about the class,
dosage, strength, duration of the prescription and the actual diagnosis associated, it is
difficult to analyze the appropriateness of the prescription. In addition, there the issue of
the different types of opioids (hydrocodone, oxycodone, codeine, etc.), as well as
immediate release vs. extended release, the number of pills, etc. Another important area
of future research has to do with the selective comparison of opioid analgesic relative to
the non-opioid analgesic. Here again, these analyses can only be conducted with the
appropriate data set and future data collection effort should be duly focused.
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There are so many aspects to the Opioid epidemic, that it requires a multidimensional approach that involves patients, doctors, APPs, clinics, medical school,
insurance companies, hospital administration, etc. This study finding does imply that
further research is needed to inform the provider education modules and develop
evidence-based protocols to help ED providers in their difficult task of prescription
decision making. Research in the area of dose-equivalence, appropriateness of
prescription, assessing pain levels, and patient’s drug-seeking behavior are all needed as
well. Critical to this issue is the collecting of information on the provider’s prescribing
practice -and its short term and long-term effects on their respective patients- requiring
longitudinal as well as patient-specific data. The current study assumes that all the opioid
prescribed were done on discharge and not administered in the ED and there is no
specification on the method of administration. The absence of this or any follow-up data
prevents any study into the possible correlation between the prescriptions and subsequent
use diversion or potential abuse disorders.
Implications
Based on reports in the media, the opioid epidemic will be around for some time
and research into the many factors involved will also continue. There is much to learn
about opioid use and abuse and how it can be avoided and the variation in the
prescription rate is an important aspect of the problem. Many studies have generated
considerable information on the patient characteristics that contribute to the variation in
prescription rates. This study’s findings have provided much need additional insight
about the conceivable role that ED providers play in the prescription rate variation that
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contributes to the opioid over-exposure that is an unfortunate part of pain management.
There is more to be uncovered, but the results of this analysis point to evidence of the
existing differences that must be acknowledged and addressed.
The importance of communicating these findings to stakeholders should not be
overlooked. The providers who deal with pain management in the ED as well as the
individual patients and those at risk who use these facilities at one time, or another should
be informed. Providers must become cognizant of the effect of their conscious and
unconscious biases, through education and information, and be trained in ways that help
them overcome these biases. Ideally, ED providers should be made to do training in
facilities dedicated to pain management, working with specialists who have experience in
dealing with the specifics of this unique field. They should also be made to understand
the biases that may be unique to their own training and background (and other yet
unidentified characteristics), because only then can they work towards proactively
overcoming them. Finally, the ED providers should assessed specifically on their
prescribing rates and this information shared with them, as there can be incongruence
between the self-perceptions of their prescription rates and the reality of that rate as is
reflected in the records (Bartley et al., 2015).
The findings also point to the need for patients to be more actively involved in the
treatment they receive, specifically the type and quantity of prescriptions from the ED
providers. These prescriptions are based, in part, on the providers’ perceptions of the
patients’ needs. If the patient fails to adequately communicate their needs, then the
treatment can be insufficient or unsatisfactory. When it comes to pain management in the
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ED, the providers have to make split second decisions and in this they can be assisted by
an informed patient. Patient need to know not just about the potential dangers of abuse of
and addiction to opioids, but also about the options that they have for pain management,
but also about the disparities and biases that may be subjected to in these settings
(Committee on Advancing Pain Research, Care, 2011). The experience of pain varies
from one individual to the next, but effective communication can make for a more
informed interaction, and therefore a more satisfactory outcome for both providers of
care and recipients of such care, and thereby minimize the potential for harm.
Conclusion
The study found that there is significant difference in the prescription rate among
the various ED provider type even when controlling for accepted patient traits such as age
and level of pain. Race and payment types were also significant predictors of the
probability of an opioid prescription, but only the later was found to interact with the
provider type variable. These findings were based on the analysis of the NHAMCS 2015
data set and provide an overall insight, but the findings are limited by the nature of the
dataset. Ultimately, the problem of opioid prescription variation, in the ED and
elsewhere, will require further research to elucidate the nature of the relationships
detected and thereby help to minimize the burden of the opioid abuse disorder on the
health care system specifically, and our on our society in general.
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